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A t the time the first pancreas transplant was performedby Kelly and Lillehei in 1966, insulin therapy for diabe-
tes was generally available but administered in a form that
is known today as “conventional therapy.”1 In this era, as
many as half of all juvenile onset diabetics did not reach
the age of 55 years. Early mortality from accelerated cardio-
vascular disease, renal failure, and hypoglycemia-related
events were commonplace. The early low success rate and
mortality of pancreas transplantation by comparison were
also suboptimal. As will be characterized in the succeeding 8
chapters, the outcome of “best medical therapy” with newer
forms of insulin and insulin delivery systems along with
dramatically improved outcomes of islet and pancreas
transplantation and novel β-cell sources hold great prom-
ise for those afflicted.
Among the great strides in diabetes research was the Dia-
betes Control and Complications Trial (DCCT).2 This trial,
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published in 1991, showed that intensive insulin therapy
when compared with “conventional therapy” dramatically
reduced the incidence and progression of the microvascular
complications of diabetes, nephropathy, neuropathy, and ret-
inopathy. Thus, with intensive insulin therapy, the mean he-
moglobin A1C was improved to 7% compared with 8.3%
in the conventional group. The improved microvascular out-
comes and measured hemoglobin A1C came at a substantial
price, namely, a greatly increased incidence of hypoglycemic
events requiring third-party intervention. After 2 decades, the
2 groups have also diverged with respect to mortality; recent
reanalysis of the original study groups demonstrates that
those individuals who received intensive insulin therapy
groups had lower overall mortality.3
Current best practice includes the availability of insulin
pumps and newer forms of synthetic insulin as well as phar-
maceutical agents that augment insulin action. Unfortunately,
the widespread application of the therapeutic measures taken
in the intensive therapy arm of the DCCT is not the norm.
Analysis of data from the 67 centers reporting to the US type
1 diabetes (T1D) exchange shows that even today, more than
20 years after the DCCT, the average hemoglobin A1C for
treated patients is 8.3%. Thus, outside of a clinical trial, such
as the DCCT, actual practice achieves suboptimal outcomes.
A remarkable report of the current state of diabetes care is
published in the Journal of the AmericanMedical Association
in January 2015. This report shows that in a modern era of
diabetes care, mortality remains higher than the general
population. For men and women, the life expectancy for
those reaching 20 years of age is 11.1 years and 12.9 years
less than the general population, respectively.4 These so-
bering findings, which have been thoughtfully summarized
in an accompanying editorial by Katz, provide a meaning-
ful context for an international conference dedicated to
summarize the current state of pancreas and islet trans-
plantation and chart the way forward with an ambitious
research agenda.5 The need for a cure for diabetes through
transplantation, stem cell–based therapy, regeneration, newer
insulin delivery systems, and devices that warn of hypoglyce-
mia have been brought into sharp focus by these reports
which show that the progress in care for diabetics has hit
a plateau. Innovation will be required to improve the qual-
ity of life and lower morbidity and mortality for those with
insulin-requiring diabetes.
Against this backdrop, the International Pancreas and
Islet Transplant Association (IPITA), in collaboration with the
Transplantation Society (TTS), held a scientific workshop in
Oxford England, May 7 to 9, 2014, to review the current
status and needed research agenda of 8 current or nascent
β-cell replacement therapies: whole organ pancreas trans-
plantation, isolated islet transplantation, artificial pancreas
(AP), immunological tolerance, xenotransplantation, encap-
sulation technologies, β cell regeneration, and stem cell
derived β cells. Thirty-two scientists and clinicians repre-
senting 4 continents, 7 countries and 29 institutions, with
dedicated expertise in these areas were recruited to partici-
pate in 8 topical workgroups along with representatives of
the NIH (National Institute of Diabetes and Digestive and
Kidney Disease, National Institute of Allergy and Infectious
Disease), Diabetes Research and Wellness Foundation, the
Juvenile Diabetes Research Foundation (JDRF) and industry.
In advance of the meeting, the workgroups prepared summa-
ries of their respective topic highlighting the state of their
field and the research agenda needed to move the therapy
forward to optimal clinical application. Presentation and
full group discussion at the meeting generated revised sum-
maries presented in the 8 sections below. These reports
are followed by the results of a conference attendee survey
examining how the participants view the future of β cell re-
placement therapies.
ALLOGENEIC PANCREAS TRANSPLANTATION
Current State of the Field
Pancreas transplantation has been available as a cure for
diabetes since its first application in 1966. The most common
application is simultaneous pancreas-kidney (SPK) trans-
plant for the uremic T1D patients who are free of major sur-
gical risks. Solitary pancreas transplants in the nonuremic
diabetic have been largely reserved for patients with brittle
diabetes and hypoglycemic unawareness despite best medical
therapy or after a successful kidney transplant. Unlike in
the European Union where the application of whole-
organ pancreas transplantation continues to expand, the
number of pancreas transplant cases in the United States
has decreased by 35% since the year 2003. The reasons
for the decline in the United States are that the number of
waitlist patients has decreased and the utilization of donor
organ pancreas has declined markedly. The decline in pan-
creas utilization in the United States followed publication
of the pancreas donor risk index (PDRI) which has created
an environment of selectivity in the United States.6 The
PDRI has also been validated in the United Kingdom.
However, the trend for pancreas utilization in the United
Kingdom and Europe is divergent with the US European
policies strongly favoring the effective use of regional
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teamwork in pancreas procurement which include policies
regarding cryopreservation solutions and the technical de-
tails of pancreas procurement. Thus, European-wide poli-
cies have led to much better pancreas utilization while
achieving excellent results. Thus, although PDRI has been
validated on 2 continents, the addition of uniform procure-
ment and preservation policies can further enhance utiliza-
tion beyond what can be achieved by the high selectivity
created by simple reliance on the PDRI alone. Country-
wide policies regarding pancreas allocation to islets and
pancreas transplantation in Australia have fostered an envi-
ronment of cooperation and better utilization.
Decreasing waitlist could be attributable to better insulin
therapies, reduced enthusiasm for pancreas transplant sec-
ondary to data showing limited survival benefit,7 and better
outcomes with islet transplantation.8 Declining organ utiliza-
tion followed publication of studies that aggregate risk fac-
tors for early graft failure. As such, transplant surgeons are
oriented to donor selection strategies that avoid early graft
failure using a predictive index. Studies on strategies to in-
crease organ utilization by avoiding early graft failure with
active interventions have been scarce over the past decade.
Donor selection and intervention studies in pancreas trans-
plant have been largely focused on early outcomes, specif-
ically avoidance of early graft loss from thrombosis and
sepsis. Studies of long-term graft survival and the impact
of pancreas transplantation on diabetic morbidity and
mortality is hampered by the lack of a clear definition of
graft failure. Without an internationally accepted endpoint
of pancreas transplant function, the literature on the im-
pact of pancreas transplantation on long-term diabetic
morbidity can be viewed as observational.
Need for Systematic, Comprehensive Documentation of
Pancreas Transplant Outcomes Worldwide
Graft failure criteria cannot be defined clearly unless the
goals of pancreas transplant are defined. Is insulin inde-
pendence the goal of all pancreas transplants? Does partial
function of the pancreas benefit the patient in providing
stable glycemic control and abrogation of hypoglycemia
unawareness? This may be especially relevant for type 2 di-
abetics (T2D) with high baseline insulin requirements. Fur-
ther, does partial function provide long-term benefit in
incidence or improvement of secondary complications?
Should pancreas transplant in total pancreatectomized pa-
tients have a dual outcome endpoint for exocrine and en-
docrine function?
One option would be to have absolute insulin indepen-
dence as the goal. This would clearly be the most accepted
and easily auditable endpoint for all patients. However, when
applied across the gamut of patients undergoing transplant, it
clearly is restrictive. Another option would be to have differ-
ent pathways for pancreas transplant with predefined end-
points for each pathway: type 1 with/without hypoglycemia
unawareness, T2D nonobese with/without secondary com-
plications, surgical diabetics (postpancreatectomy), and
so on. This would require a well thought out algorithm,
with clear endpoints in each limb and additional data, such
as C-peptide, HbA1C, quantification of insulin require-
ment, and details on hypoglycemia unawareness and sec-
ondary complications to name a few. Currently, none of
the abovementioned variables are collected by the United
Network for Organ Sharing for the Scientific Registry of
Transplant Recipients outcome analysis.
Another important attribute of a system defining organ
function endpoints should be verifiability. Currently, pan-
creas graft failure is self-reported, and because the definition
is vague, available data may be regarded as unreliable. Death
in most countries can be verified using census or other gov-
ernmental databases. Insulin use and oral agents can be
tracked based on prescription data obtained from third-
party payers.9 Clear auditing guidelines need to be estab-
lished for any outcome endpoints.
There is opportunity to learn from our islet transplant
colleagues in maintaining a detailed database resulting in
the ability to look at outcomes with well-defined criteria.10
If the Collaborative Islet Transplant Registry database were
to be linked with the UNOS database for pancreas trans-
plants, both databases would be enhanced with the ability
to compare “apples to apples”. Granted, the total number
of patients is smaller and at least the current funding in the
United States is inadequate. Any attempt to increase the gran-
ularity of data in pancreas transplantation is met with re-
sistance from the centers largely due to the “unfunded
mandate” issue when it comes to data reporting.
Any effort to impact pancreas transplantation positively in
the next 10 years will have to start with crystallization of
functional endpoints that are widely accepted and verifiable.
If achieved, this would lead to a better understanding on the
relative impact of pancreas transplants on the burden of dia-
betes in comparison with other options.
The Research Agenda
Indications for Pancreas Transplantation
The majority of solid organ pancreas transplants are
carried out in patients with chronic renal failure associ-
ated with T1D. In patients not yet requiring dialysis, the
timing of transplantation is based on the anticipated
timepoint of needed renal replacement therapy. Typically,
a glomerular filtration rate (GFR) of 20 mL/min is ac-
cepted as the upper limit of renal function at which it is
reasonable to list a patient for a SPK transplant—this is
partly driven by the need for equity with respect to other
patients competing for donor kidneys.
Assessment for pancreas transplantation is substan-
tially focused on cardiovascular risk—the majority of pa-
tients with diabetic renal failure have some significant
degree of cardiovascular disease. Units have developed
different protocols to assess this, most including some
modality of myocardial functional testing (perfusion scin-
tigraphy, echocardiography, cardiopulmonary exercise test,
and so on). Research into the predictive ability of these and
other factors is needed. Age is a good predictor of cardiovas-
cular disease in this population of patients, and in most
patients older than 60 years, the risk-benefit of the com-
bined procedure is judged to be unfavorable. In patients
judged to be at a lower risk of perioperative cardiovascular
complications, there is consistent circumstantial evidence
of the life expectancy benefit of combined pancreas and
kidney transplantation.11
The place for SPK transplantation in patients with T2D
is incompletely defined, although this procedure is carried
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out in increasing numbers by a several units.12,13 Numer-
ous questions require answers: Does transplantation pro-
vide similar long-term benefit as in T1D? Should this be
restricted to noninsulin-resistant patients? Should this be
restricted to nonobese patients? These and other questions
should be addressed by collaborative and carefully de-
signed clinical trials. In patients who do not require renal
replacement therapy, the evidence that pancreas transplan-
tation prolongs life is less clear. Recurrent episodes of hy-
poglycemia, often driven by the desire for tight control
and long-duration diabetes, are both life-threatening
and highly disruptive to lifestyle, and this is the most
widely accepted indication for pancreas transplantation
alone. Many patients, however, are not unaware of their
hypoglycemia but may nonetheless be very compromised
by the complications of diabetes. In particular, patients
with rapidly progressive retinal, renal, or neurological
complications are often referred for consideration of pan-
creas transplant alone (PTA).
This creates problems for a number of reasons: first,
the outcome of PTA is poorer than that of SPK in nearly all
published series, reducing any advantage of normalising pan-
creatic function. Second, the effect of successful pancreas
transplantation with respect to halting the progression or re-
versing the secondary complications of diabetes has not been
convincingly documented in randomized trials. There are
many publications based on limited numbers in uncon-
trolled, observational studies, and the consensus from these
shows a beneficial effect; however, publication of positive
observation studies may be hampered by publication bias:
negative studies are unlikely to be published. However, the
quality of evidence is poor, and the risk of publication and
other forms of bias considerable. It is clear that a scientifi-
cally rigorous approach to this issue is needed to establish
the true benefit of PTA beyond reducing hypoglycemia un-
awareness. Diabetic patients who undergo PTAmay contrib-
ute greatly to our knowledge of pancreas transplantation:
such patients often have less-advanced secondary complica-
tions of diabetes, and longitudinal studies in such patients
may provide key information as to the effect of pancreas
transplantation on the progression of diabetic retinopathy,
neuropathy, vasculopathy, and nephropathy. Similar studies
in SPK transplant recipients (with established renal failure)
are compromised by the very advanced stage of secondary
complications—for example, it is hard to measure the effect
of pancreas transplantation on retinal disease in a patient
who has already received extensive laser therapy.
Another problematic group of patients are those with a
significant degree of renal impairment, but not close enough
to requiring renal replacement therapy (typically GFR 35 to
45mL/min) to warrant kidney transplantation. Such patients
are not generally eligible for SPK transplant listing and are
usually denied PTA listing aswell, because of the concern that
the effect of calcineurin-inhibitor therapy might accelerate
the decline in renal function and bring forward the need for
dialysis. Such patients, therefore, are often denied transplan-
tation until such time as their renal function has deteriorated
(see above), and often express concern that they are placed
at risk of deterioration of nonrenal complications in the
meantime. In fact, the degree to which renal function dete-
riorates under these circumstances is not clear, and some
evidence suggests that this might be less than was once
thought.14 This requires further investigation, particularly
with the use of non-nephrotoxic immunosuppressive drugs
(sirolimus, belatacept), that have not been formally tested
in the context of pancreas transplantation.15,16
Pancreas Preservation
The majority of pancreas transplant units rely on static
cold preservation using University of Wisconsin, histidine-
tryptophan-ketoglutarate or Celsior solutions. The majority
of published studies suggest no difference between these solu-
tions, although there are 2 publications, which suggest inferior
outcomes in histidine-tryptophan-ketoglutarate-preserved or-
gans17,18 especially with donation after circulatory disease
(DCD) organs and longer preservation times.
Cold ischemia time is an important factor in graft outcome,
with a hazard ratio of 1.13 in the Donor Risk Analysis of
Axelrod et al.6 The combination of several risk factors (eg, older
age, longer cold ischemia time, DCD status) has a substantial
impact of the likely outcome of pancreas transplantation. There
is clearly a strong argument to develop a means of preservation
that reduces the ill effect of longer preservation times.
The use of the “2-layer” method, whereby the organ is
suspended at the interface between University of Wisconsin
solution and the oxygen carrier perfluorocarbon, is effective
in small animal models of pancreas preservation, in the con-
text of islet isolation. In human pancreases, this method also
shows a benefit in organs initially preserved in University
of Wisconsin solution and those preserved for a prolonged
time,19,20 but has not been subjected to a randomized trial
in solid organ transplantation.
Hypothermic machine preservation (HMP) has become
increasingly popular in the preservation of marginal and
DCD kidneys and is of proven outcome benefit in the context
of expanded criteria donor organs. However, there is very lit-
tle published information in the pancreas. Leeser et al21 car-
ried out HMP in 4 human pancreases and demonstrated
improved islet function after isolation, but there are also con-
cerns that HMP may be damaging to the very fragile endo-
thelium of the pancreas.
Oxygen delivery is increasingly recognized as important in
organ preservation, particularly of marginal organs. Experi-
mental work in the porcine pancreas suggests that venous ox-
ygen persufflation at ice temperature effectively improves the
viability of the pancreas, and clinical studies are planned.22
There is much interest in normothermic machine perfu-
sion in the context of the lung,22 kidney,23 and liver.24
Early attempts to perfuse the pancreas in the same way have
been problematic, and perfusions of more than a few hours
have not proved successful in experimental models.
Two-layer preservation, persufflation, HMP, and nor-
mothermic machine perfusion are all potential targets for
clinical research studies, although the technical challenges
of machine perfusion (especially normothermic) are not
yet sufficiently solved to warrant clinical studies immedi-
ately. Key endpoints in such studies would need to include
surrogate markers of ischemia-reperfusion injury and re-
perfusion pancreatitis.
Immunosuppression
Immunosuppression after pancreas transplantation fol-
lows a consistent pattern in almost all units. Induction
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therapy is almost universally used, with either nondeplet-
ing antibody treatment (basiliximab) or depleting anti-
body treatment (thymoglobulin or alemtuzumab). There
is little systematic evidence as to which of these is better
in the context of pancreas transplantation, although there
is evidence from kidney transplantation that alemtuzumab
is superior to basiliximab as a means of minimizing rejection
in low immunological risk patients and that alemtuzumab is
equivalent to Thymoglobulin with respect to rejection but
may be superior with respect to postoperative infection.
There are several publications with respect to alemtuzumab
in pancreas transplantation25-27 but the only reported ran-
domized trial is unpublished.28 Although there has been no
adequately powered randomized trial of induction therapy
in pancreas transplantation, it is unlikely that this would pro-
vide meaningfully different guidance to that which is emerg-
ing from kidney transplant studies.
Steroid avoidance (or sparing) is particularly desirable in
pancreas transplantation, and there is evidence from several
quarters that the use of alemtuzumab induction enables this
to be achieved safely.
Within maintenance therapy, the majority of units use
tacrolimus-based immunosuppression; cyclosporine is rarely
used as primary therapy although it is used as a secondary
therapy in cases of tacrolimus intolerance. The importance
of tacrolimus nephrotoxicity (and β-cell toxicity) is de-
bated, and there is a view among some clinicians that the
current low tacrolimus level regimens that followed the
Symphony study have substantially altered the risk profile
of this drug.29 However, many clinicians believe that the
long-term use of calcineurin-inhibitor medication does limit
the lifespan of the kidney and that a non-calcineurin inhibitor
maintenance regime is desirable. This view is strongly sup-
ported by the findings of Budde et al.30
Patients with an intermediate level of renal dysfunction
pose a specific problem. Such patients may not have a suffi-
cient level of renal function to be able to tolerate safely the in-
cremental deterioration in renal function that my occur with
tacrolimus, but do not qualify for a combined pancreas and
kidney transplant, being still some years away from the need
for dialysis. In this group of patients, trials of novel immuno-
suppression would be of interest, although the numbers of
patients that fulfil the description make the design of a phase
3 trial challenging.
Innovative immunosuppressive regimes might include the
use of belatacept and/or sirolimus. Neither drug has the im-
munosuppressive potency of tacrolimus and would need to
be combined in such a way to provide adequate protection
from rejection. The use of alemtuzumab may achieve this,
or possibly, the use of tacrolimus during the early, high-risk
period postoperatively. Kidney transplant trials of sirolimus
have generally suggested that this is a drugwhichmay be best
introduced at an interval after transplantation. Belatacept
has been tested in kidney transplant patients and shown to
be nontoxic and well tolerated, albeit with higher rejection
rates than cyclosporine. The combination of belatacept and
sirolimus has recently been tested,31 with and without the ad-
dition of donor bone marrow (which appeared to have little
effect on outcome in this small study). The association with
posttransplant lymphoproliferative disorder in Epstein-Barr
virus-negative patients is of concern, although this is an un-
common scenario in adults.
Further opportunities will come with the use of cell ther-
apy. Early trials of T regulatory (Treg) cell strategies are
now in progress in kidney and liver transplantation, and
early-phase studies in the use of mesenchymal stem cells have
generated optimism.32 The pancreas may be a good environ-
ment for the phase 2 studies that such strategies will need.
Immune Monitoring and Clinical Assessment of the
Failing Pancreas Transplant
Monitoring the graft postoperatively is probably the
greatest challenge in pancreas transplantation. Particularly
in solitary pancreas transplantation (in which there is no
donor-specific kidney to help with graft monitoring), graft
surveillance is very subjective—the move away from blad-
der drainage, although desirable for many reasons, has re-
moved a useful biochemical marker of allograft function. It
is very likely that this is an important factor in the higher
rate of late graft loss in this group of patients. Trials of immune
monitoring are in progress in both kidney and pancreas
patients to try to identify an “immunological fingerprint”
that predicts imminent rejection.33
Other approaches to immune surveillance include en-
doscopic biopsies—facilitated by placing the graft in a
more accessible location with the duodenal anastomosis
to the proximal jejunum or duodenum.34,35 Percutaneous
biopsy is carried out by many units, but generally as a diag-
nostic (ie, confirmatory) test rather than for surveillance.
The hypothesis that portal venous drainage is preferable
with respect to the alloimmune response is unproven but
may be a viable area for research particularly in the context
of more sophisticated methods of diagnosing an early im-
mune response. A small number of units routinely drain the
pancreas into the portal venous system, although there is
a lack of good evidence for an outcome benefit.36 The im-
munologic monitoring for pancreas transplant recipients
has largely been directed at conventional monitoring of
the alloimmune response. Unfortunately, this monitoring
has been ineffective at monitoring the reoccurrence of the
autoimmune response. Recipients of pancreas transplants
are presumed to be “preimmunized” in terms of having mem-
ory autoreactive cells. To design more selective and effective
(and possibly milder) immunosuppressive approaches, it is im-
portant to establish validated techniques capable of accurately
monitoring both alloreactivity and autoreactivity. It is also
important to recognize that insulin resistance in the ab-
sence of an immune response can contribute to graft fail-
ure. Along these lines, standardized metabolic testing will
be essential to differentiate between graft failures secondary
to insulin resistance versus an autoimmune or alloimmune
response to treat reversible causes of endocrine insufficiency.
Finally, an accurate assessment of graft failure (resistance ver-
sus β-cell loss) will facilitate more accurate definitions of
graft function for utilization in registry data.
Pretransplant Screening of the Pancreas
Transplant Recipient
The immunologic screening for recipients of SPK transplants,
pancreas after kidney transplants, and PTA is essentially di-
rected at the same immunologic work-up as performed for
kidney transplantation. This work-up is only directed at the
detection of alloantibody, but there is literature that suggests
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that pretransplant work-up looking at markers of autoim-
munity should also be considered. The monitoring of the au-
toimmune response can include the measurement of titers of
autoantibodies associated with T1D, including glutamic acid
decarboxylase, IA-2, islet-specific glucose-6-phosphatase cat-
alytic subunit-related protein, and ZnT8. It is unclear what
clinical relevance these autoantibodies may have as it relates
to whole organ transplants. However, there is evidence that
the detection of a cellular response against autoantigens be-
fore transplantation is predictive of outcome (see below).
Prescreening for the autoimmune response before transplan-
tation may have even a higher relevance of the scenario of
retransplantation. The immunologic screening before trans-
plantations is an area which needs further investigation.
The presence of an autoimmune response before transplanta-
tion may guide the choice of immunosuppression. Whether
current methods of immunosuppression can block the mem-
ory response associated with autoimmunity is uncertain.
Most transplant centers are evolving to the “virtual”
crossmatch for screening compatible donors. This requires
single-antigen luminex beads to identify relevant anti-
major histocompatibility complex antibodies which should
be avoided for a given donor. The use of flow cytometry to
detect T-cell and B-cell alloreactivity using flow cytometry
can also be used, but, for cost reasons, may be limited to
highly sensitized recipients. Currently, pretransplant im-
mune monitoring is limited to the standard detection of
preformed alloantibody. The role of an additional screen
for markers of autoimmunity may provide further guid-
ance with respect to immunosuppressive strategies and
their impact on the autoimmune response.
Assessment of the Failing Pancreas Allograft
Pancreatic allograft dysfunction can be a gradual process
and is frequently asymptomatic. It can be detected by a grad-
ual escalation in Hgb A1C, or incidental elevations in serum
amylase and lipase. Unfortunately, it is frequently discovered
by the new onset of hyperglycemia. Early detection is imper-
ative to identify reversible causes of graft dysfunction. Broad
consideration for the etiology of dysfunction include:
alloimmune rejection, recurrent autoimmunity, insulin
resistance (T2D), chronic calcineurin inhibitor toxicity,
graft pancreatitis in the absence of rejection, cytomegalo-
virus, posttransplant lymphoproliferative disorder, and
bacterial or fungal infection. An algorithm to distinguish
between the above factors requires a standardized clinical
assessment. The clinical assessment should be triggered by in-
cidental elevations in serum amylase and lipase, a gradual in-
crease in fasting blood sugars and/or an increasing HgbA1C
or hyperglycemia. The assessment should include an ultra-
sound of the pancreas with Doppler, and potentially magnetic
resonance imaging or computed tomography depending on
the expertise at the center. Blood cultures and cytomegalovirus
cultures should be performed if there is suspicion for an infec-
tious etiology.
Although ultrasonography can provide indirect evi-
dence of acute rejection, its most important application is
to guide a percutaneous needle biopsy using an 18 gauge
core biopsy needle. Poor visualization of the pancreas second-
ary to adjacent bowel or patient body habitus may preclude
transcutaneous biopsy. Occasionally, a suitable window can
be found with CT guidance, and rarely an open/laparoscopic
biopsy is required. In the absence of a biopsy, a suspicion for
acute rejection can be made based on ultrasonography find-
ings and laboratory findings consistent with rejection (elevated
lipase/amylase). Gene signatures associated with rejection
have been validated for both kidney and liver transplanta-
tion, but not pancreas transplantation.37 Of equal signifi-
cance, the rejection “signature” appears before the clinical
onset of rejection. Serummarkers for rejection in the scenario
where a pancreas biopsy is unattainable would be particularly
helpful. Unfortunately, these markers need to be validated for
pancreas transplantation, and validating gene signatures for
both alloimmunity and recurrent autoimmunity should be
done. The ability to pick up signals of recurrent autoimmunity
as well as the development of a de novo alloimmune response
before clinical deterioration would greatly facilitate the man-
agement of the pancreas transplant recipient. The availability
of tissue greatly facilitates the ability to distinguish between
the multiple etiologies leading to pancreatic graft dysfunc-
tion. The Drachenberg/Banff guidelines for the diagnosis of
rejection were recently updated and will not be reviewed
herein.38 Early recurrent autoimmune disease can be iden-
tified by islet-centered lymphocytic inflammation (isletitis),
but more frequently late recurrent disease is associated with
the absence of insulin producing β cells using immunohisto-
chemical stains.
Immune Monitoring of the Alloimmune and
Autoimmune Response
There is an increasing amount of data demonstrating
serologic markers of alloimmunity and autoimmunity associ-
ated with pancreatic graft dysfunction. Again, it is unclear
what the significance of the autoantibodies (GAD, IA-2,
IGRP, ZnT8) associatedwith diabetes is in terms of the devel-
opment of dysfunction. In islet transplantation, the increase
in these titers and epitope spreading was associated with
graft loss.39 Other reports could not find an association be-
tween autoantibody and islet graft outcome.40 With regards
to the findings of autoantibodies and pancreas transplanta-
tion, Sibley41 found that there was no evidence of autoim-
mune recurrence in non-HLA identical recipients and no
islet cell autoantibodies. However, Bosi et al42 found that 9
of 23 pancreas transplant recipients (non-HLAmatched) de-
veloped ICA antibodies and 7 of 9 went on to develop graft
loss with 2 to 35 months after detection. There have been
more recent reports of increasing autoantibody titers and epi-
tope spreading in recipients of pancreas transplants that were
associated with inferior outcome.43
Interestingly, there are an increasing number of reports
suggesting that monitoring the cellular response against
autoantigens is strongly associated with graft dysfunction.
Much of this literature relate to islet allograft survival and
will not be reviewed, but is nicely summarized in a review
from Abreu and Roep.44 The assays for monitoring the
cellular response to autoantigens have not been standard-
ized, but effective assays that can be validated and per-
formed at multiple laboratories will be an important
advancement. The most elegant demonstration of recur-
rent autoimmune disease after whole-organ pancreas trans-
plantation came from Vendrame and demonstrated the
progression of allograft dysfunction associated with the
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development of autoantibodies and a CD4− T-cell response
against GAD.43 These autoreactive cells were isolated from
biopsies and detected and sorted using class II tetramers.
When these were cotransplanted with human islets into
immunodeficient mice, they caused diabetes. In the same
report, other CD8+ lymphocytes reactive against IGRP
autoantigen were detected using class 1 pentamers. A more
recent report from Japan shows similar evidence for recur-
rent autoimmune disease after SPK transplantation from a
DCD donor.45
Clearly, a standardized/validated approach to moni-
toring autoreactive cells with different specificities will
be important prognostically and will help guide the im-
munosuppressive interventions to prevent graft loss after
pancreas transplantation. At the same time, these studies
may provide insight into the etiology of late graft loss in
the absence of an alloimmune response. The tetramer-based
assays are compromised by the large volume of blood nec-
essary to detect responsive cells. Other assays using major
histocompatibility complex multimers permit direct ex vivo
quantification of autoreactive cells and require significantly
less blood.46 This assay, the Diab-Q kit, requires low blood
volumes, and its results correlated with clinical outcome in
islet recipients. Another monitoring strategy determines the
cellular response against overlying peptides of the auto-
antigen GAD.47 Although this assay has not been validated,
it is attractive in that the assay is not HLA restricted.
Insulin Resistance
Finally, pancreatic graft insufficiency/failure may be
related to the development of insulin resistance in the
absence of alloimmunity or autoimmunity. In these cases,
recipients may have a gradual increase in fasting glucose,
or a gradually escalating Hgb A1C. This may be related
to weight gain, steroid use, or calcineurin inhibitor toxic-
ity. Because all of these may be reversible, it is important
to determine whether increases in fasting glucose and
Hgb A1c are related to insulin resistance. The gold stan-
dard for determining insulin resistance is a clinical research
center-based assessment using the euglycemic-hyperglycemic
clamp studies. These studies are labor intensive, and require
a stay in a clinical research center, thus are not adapted to
office-based assessment of pancreas transplant function.
However, the homeostasis model assessment of insulin re-
sistance is gaining widespread use as a result of its simplic-
ity and validity and is based on fasting blood glucose (FBG)
and insulin levels.48 The homeostasis model assessment
score correlates well with the euglycemic-hyperglycemic
clamp in terms of assessing insulin resistance after pan-
creas transplantation. The detection of insulin resistance is
important, in that it may be reversible by altering immunosup-
pression, weight loss, addition of oral hyperglycemic agent, or
glucagon-like peptide (GLP)-1 agonists.
In summary, a complete clinical assessment of the failing
pancreas graft should differentiate between alloimmunity, re-
current autoimmunity, and the development of insulin resis-
tance. Because treatment for each of these etiologies leading
to poorer glycemic control requires different strategies, ap-
propriate immunomonitoring and metabolic testing may
be able to identify reversible causes for graft dysfunction
and loss. Standardization of these noninvasive assays for
monitoring the alloimmune and autoimmune responses,
as well as metabolic testing for insulin resistance, will pro-
vide essential data in terms of early intervention to prevent
graft loss. Nonetheless, the validation of noninvasive markers
of recurrent autoimmunity as well as metabolic tests for
insulin resistance represents a major “gap” in pancreas
transplantation. At the same time, validated tests to differ-
entiate between causes for graft insufficiency/failure will be
extremely useful in terms of accurately reporting outcomes
of pancreas transplantation.
Prospective Randomized Comparison of Pancreas and
Islet Transplant Outcomes With Best Medical Therapy
Prolonged insulin independence (47% at 3 years) has been
demonstrated in the modern era of islet transplantation.49
In addition, selected groups have reported 50% or greater
5-year insulin independence rates in islet transplants,50
thus comparing it favorably to solitary pancreas trans-
plants. This comparison, despite its weaknesses, compels
us to strongly consider a prospective randomized trial
comparing pancreas and islet transplants.
There are obvious challenges to designing and conducting
this trial—when is the right time (pending Food and Drug
Administration [FDA] application for registration of islets
as a therapeutic agent), what is the design—randomization
points and patient counseling. Early randomization could
lead to a high patient dropout rate, late randomization
may lead to patient apprehension about not knowing
whether they would undergo major surgery). Several addi-
tional questions arise, particularly reimbursement issues.
Inclusion and exclusion criteria could be controversial.
The typical islet recipient (low body mass index, low insulin
requirements, early or no secondary complications) is not the
typical pancreas transplant recipient. Whether patient selec-
tion as currently performed would need to change to enable
a clinical trial is an area of uncertainty. Another important
consideration is whether the best medical therapy should be
compared with both transplant options. Can we get the pa-
tients and endocrinologist investigators on board?
Despite these challenges, if this trial can be performed
credibly and successfully, it will go a long way in answering
key questions that could shape the trajectory of both pan-
creas and islet transplants in the future. In addition, it will
provide a unique opportunity for cross-fertilization and col-
laborative efforts between investigators that have been previ-
ously focused solely in the pancreas or islet transplant fields,
as well as the endocrinology community.
Secondary Complications and Mortality
The impact of pancreas transplantation on secondary
complications of diabetes has been documented by several in-
vestigators. Most notably, in patients with T1Dmellitus who
did not have uremia and have not received a kidney trans-
plant, pancreas transplantation did not ameliorate estab-
lished lesions of diabetic nephropathy within 5 years after
transplantation, but did so at 10 years posttransplant.51
Improvement in motor, sensory, and autonomic indices in
patients with diabetic neuropathy after pancreas transplanta-
tion has been reported.52
At the Manchester Royal Infirmary, 20 SPK transplant re-
cipients were studied before and 6 months after SPK trans-
plantation; these were compared with 15 normal volunteers
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using retinal confocal microscopy: SPK transplant recipients
compared with normal controls had a marked decrease in
nerve fiber morphometry and nerve fiber length and density
dramatically improved.53
Thus, the beneficial effect of pancreas transplantation
on diabetic retinopathy seems highly logical. However,
studies to date do not use strict case-control method com-
paring transplanted patients versus untransplanted con-
trols. Also, risk factors, such as blood pressure, baseline
degree of disease, renal function, and type of immunosup-
pression, are not controlled.
Does Pancreas Transplantation Protect the
Kidney Transplant?
The effect of pancreas after kidney (PAK) on the kidney
transplant has been marred by controversy due to lack of
clear controlled data. One United States Renal Data System
study of PAK in diabetic kidney recipients showed PAK was
protective of renal function in all groups, and documented
that a GFR between 30 and 39 mL/min was a risk factor
for kidney failure after PAK.54 In a long-term study (5 years)
of the efficacy and safety of pancreas transplantation alone, it
was shown that in 51 patients with sustained pancreas trans-
plant function, kidney function (serum creatinine and glo-
merular filtration rate) decreased over time with a slower
decline in recipients with pretransplant filtration rate less
than 90 mL/min.55
Live donor kidney (LDK) transplant alone has been shown
to provide a survival advantage in T1D patients compared
with deceased donor transplantation. Moreover, recipients
of an SPK transplantation had statistically significant patient
and kidney graft survivals compared with those T1D patients
who received a kidney transplant alone.56 Interpretation of
Young's data is difficult because the donors for those who
received a deceased donor kidney (DDK) alone were signif-
icantly older than the donors of SPK transplantations.
Nevertheless, it appears that kidney survival after multi-
variate analysis appeared to be superior when a pancreas
transplant was performed simultaneously. It has been
shown that early pancreas graft failure in SPK transplant
recipients is associated with an increased risk for subse-
quent kidney failure and death.11 Patients with end-stage
renal disease and T2D have been shown to benefit from
SPK transplantation in a selected series. A commonality
of most of these series is that the T2D recipients were not
obese and did not have excessive insulin requirements.
Thus, lean, insulinopenic T2D have similar outcomes as
T1D recipients of an SPK transplant. Sampaio et al57 showed
that T2D recipients of SPK transplants were not at increased
risk for death, kidney failure, or pancreas failure when
compared with recipients with T1D.
Attempts to document clear survival benefit after pan-
creas transplantation have been hampered by limitations
and controversy. A large study looking at 4-year survival
for transplanted patients versus those on the waitlist sug-
gested a survival benefit in SPK transplantation but a sur-
vival disadvantage in PAK and PTA.7 However, the same
population was reanalyzed by a different group showing
survival benefit for all groups of pancreas transplants—
SPK, PAK, and PTA.58
Thus, studies on the effect of pancreas transplantation on
patient survival have been affected by the lack of control
for renal function, lack of comparability of study groups:
SPK versus DDK versus LDK. They have been highly im-
pacted by selection bias (choosing ideal patients for transplan-
tation) and not controlling for the effect of renal function over
time. Further, patient risk factors allocated to choice be-
tween SPK, DDK, and LDK are not the same.
Proposal for a Randomized Trial in
Pancreas Transplantation
Dowe need a randomized trial comparing SPK versus kid-
ney transplant alone? There are significant factors that would
support the rationale for such a trial. Animal studies of ben-
efit are compelling. Nevertheless, the best medical therapy
of diabetes has improved dramatically with progressive re-
ductions in diabetes related mortality and improvement in
quality of life. Studies in the past asserting SPK transplant's
benefits are poorly controlled especially for renal function.
Case selection bias inherent in prior studies can be overcome.
Outside the transplant community, pancreas transplanta-
tion is not accepted, particularly among endocrinologists.
This is further complicated by the fact that the endpoint of
pancreas transplant function has never been clearly defined.
It is acknowledged that among members of the pancreas
transplantation surgical community that pancreas transplan-
tation is effective at reducing mortality and arresting second-
ary diabetic complications. As such, most would suggest that
the time has passed for a randomized trial of SPK transplan-
tation versus kidney transplantation alone. A strategy for
analyzing the impact of transplantation-based β-cell re-
placement on mortality and renal function (as well as other
secondary complications) would be for a head-to-head
randomized trial of pancreas and islet transplantation. Re-
cent reports of near equivalence in the 5-year graft survival
of PTA and islet transplant alone (ITA) make a head to
head trial appropriate. Based on these considerations, the
following trial is proposed comparing pancreas and islet
transplantation. The SPK transplantation could be com-
pared with simultaneous islet kidney (SIK) transplants. In
this head-to-head trial, the assumption will be made that
no control group receiving a kidney alone is feasible both
because the vast majority of the transplant community
consider kidney transplant alone inferior to SPK trans-
plantation. Moreover, patient acceptance and knowledge
of SPK transplantation is very high. Consequently, enroll-
ment in a trial comparing SPK and SIK transplantations to
kidney transplantation alone is likely infeasible. However,
nonuremic diabetics receiving either ITA or PTA or previ-
ously kidney-transplanted diabetics receiving a islet-after-
kidney transplant (IAK) or PAK could be randomized to
a third arm of untransplanted controls. In the case of IAK
and particularly PAK, there remains significant scientific dis-
agreement regarding the potential benefit of pancreas
transplantation on mortality, future renal function, and
other secondary complications.
Summary of Research Priorities
(1) Develop carefully designed, well-controlled clinical trials
that define the impact of pancreas transplantation onmor-
tality and secondary complications, particularly renal func-
tion. Developing validated measures of pancreatic organ
function will be required for success.
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(2) The greatest obstacle to growth of pancreas transplanta-
tion is low organ utilization rates. Preservation strategies
leading to improved early graft survival and function and
increased utilization are needed.
(3) Concern about new onset and recurrent renal dysfunc-
tion markedly limits growth of pancreas transplantation.
Clinical trials of non-nephrotoxic immunosuppression
are needed.
(4) Detailed clinical studies verifying the risk of recurrent
disease are needed to exclude other causes, such as
β-cell exhaustion and alloimmune causes. Refine immu-
nologic detection and prevention strategies against re-
current autoimmunity.
Two parallel randomized trials of whole organ pancreas
versus isolated islet transplantation are recommended:
(a) SPK versus SIK, and (b) PTA and PAK versus ITA and
IAK versus best medical therapy.
ISLETALLOTRANSPLANTATION
Current State of the Field
Over the last 10 years, islet allotransplantation has de-
veloped into an established treatment modality for subjects
with T1D complicated by hypoglycemia unawareness, and
the procedure is currently reimbursed for this indication in
several countries. At present, the primary goal of islet trans-
plantation should be optimal glycemic control without severe
hypoglycemia, rather than insulin independence. Impor-
tantly, this must be routinely achievable with a single islet
infusion. A standardized approach to evaluation of clini-
cal outcomes will be essential for further developments in
β-cell replacement.
A recently completed multicenter prospective phase 3
study59 demonstrated that:
(1) Islets can be manufactured reproducibly at multiple sites
using a common manufacturing process.
(2) Independence from exogenous insulin can be achieved in
about half of islet recipients at one year from infusion,
with 1 or 2 infusions needed.
(3) Glycemic control is excellent even when insulin indepen-
dence is not achieved.
(4) Hypoglycemia unawareness is treated effectively by islet
transplantation, with associated freedom from severe hy-
poglycemic events.
Islet allotransplantation is also an acceptable therapy
for patients with end-stage renal failure and T1D, either si-
multaneously with or after kidney transplantation.60 A
comparison between islet and pancreas transplantation
in combination with a kidney transplant demonstrated
achievement of similar HbA1c levels in the 2 groups. Islet
recipients were less likely to achieve insulin independence,
whereas pancreas recipients had substantially greater
procedure-related morbidity.61
Because of the limited overall availability of human or-
gan donors, islet allotransplantation is unlikely to provide
a cure for all those affected with uncomplicated T1D, unless
islet expansion becomes a reality. In addition, “closed-loop-
systems” using implantable glucose sensors to control in-
sulin administration may enable good metabolic control
without the need for systemic immunosuppression in
uncomplicated T1D.62 However, we fully anticipate that
improvements in the outcome of islet transplantation will,
within 5 to 10 years, make islet transplantation an appropriate
therapy not only for the current indications of hypoglycemia
unawareness and grossly unstable glycemic control, but also
for all people currently considered eligible for pancreas trans-
plantation. Many of the recent and future advances in islet
allotransplantation will benefit clinical islet transplanta-
tion overall in the future. This applies whether stem cell or xeno
sources are used as the alternative cell source and/or immune
tolerance or immunoisolation protocols are used to obviate
the need for immunosuppression. To achieve these goals, how-
ever, a number of obstacles need to be overcome.
Pancreas Allocation
In most countries, allocation of donor pancreases for
whole pancreas transplantation still takes priority over
pancreases for islets.63 Clearly, if reimbursement for islet
transplantation is implemented, parity of organ allocation
is essential for the islet transplant service to be effectively
delivered. The United Kingdom has pioneered a joint pan-
creas allocation system which is currently being evaluated.
It is based on a point system and organs allocated to the
matched patient at the top of the joint waiting list, regard-
less of whether they are listed for whole organ or islets. Over-
all, it is important that any decision to allocate donors with
specific characteristics preferentially to pancreas or islet
transplantation should be based on rigorous studies of
clinical outcomes.
“Competition” Between Whole Pancreas and
Islet Transplant
Whole pancreas and islet transplantation are still often
seen as competing therapies.64 This is not only the case
for organ allocation, but also for patient referral and pa-
tient selection. Using analysis of stratified outcome data,
we need to work toward unified, joint programs of β-cell
replacement, with treatments tailored to individual patients,
rather than treatments being largely dictated by referral
patterns and physician preference. We anticipate that, within
5 to 10 years, islet transplantation will be the preferred
therapeutic procedure for β-cell replacement, as a result
of the metabolic efficiency and the superior safety profile
of the islet in relation to pancreas transplantation. How-
ever, in the meantime, it is essential that these 2 different
modalities are considered complementary, rather than in
direct competition.
Funding and Reimbursement
The encouraging results of islet transplantation over the
past decade mean that, from a clinical point of view, islet
transplantation can rightly now be considered as a clinical
treatment rather than an experimental tool. However,
for this transition to be fully realized in terms of islet trans-
plantation becoming a standard therapy worldwide, full
reimbursement by health care providers needs to be
implemented. Although this has been achieved in a num-
ber of countries around the world (eg, United Kingdom,
Switzerland, Canada, and so on), this remains an ongoing
challenge in many countries including the United States.
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Regulation
Over the last decade, islet isolation has become a highly
regulated procedure in most countries. This has added enor-
mously to the cost and complexity of the isolation procedure
and as a result has propagated the importance of islet trans-
plant networks, in which 1 or 2 centers isolate human islets
within “state of the art” designated isolation facilities for a
network of implanting centers.
The degree of regulation of pancreatic islets and the path-
way to licensure for an islet product vary in different coun-
tries.65,66 However, all islet isolation and islet transplant
teams must work with their regulatory bodies to ensure that
islet personnel are closely involved in the development and
interpretation of the cell processing regulations, rather than
them simply having them imposed from the outside.
The Research Agenda
Pancreas Procurement, Preservation, and Islet Transport
To expand the donor pool, novel strategies of optimized
pancreas procurement, pancreas preservation, and islet
transport are essential. First, a unified approach to optimal
pancreas retrieval during organ procurement is essential,
regardless of whether the pancreas is being procured for
whole organ or islet transplantation. Indeed, several stud-
ies have demonstrated that a dedicated surgical team cur-
rently is the most important determinant for the clinical
outcome of islet allotransplantation.67 Second, research into
the optimal approach to pancreas preservation, whether
persufflation, normothermic perfusion, or perfluorocarbon
incubation68-70 is vital (see previous section on whole organ
transplantation). Finally, the stringent regulation associ-
ated with human islet isolation described above, means
that islet isolation/islet transplant networks will increas-
ingly become the norm. Ideally, each islet isolation facility
should support a population of 10 to 20 million. However,
for networks to realize their full potential, optimization of
islet transport and more efficient systems for islet shipping
need to be developed.
Optimization and New Strategies for Islet Isolation
Although great progress has been made in standardization
of islet isolation, significant improvements are still needed.
The pancreas digestion step, in particular, remains an empiric
undertaking, dependent on the relatively haphazard interac-
tion of administered bacterial enzymes with the endogenous
enzymes of the donor pancreas. In addition, currently the
same techniques are used regardless of the huge variability
in human donors. Research efforts should focus on under-
standing the detailed molecular ultrastructure of the pan-
creatic islet-exocrine matrix in the full range of donors
(age, BMI, and so on)71 and on developing new, targeted
clinical grade enzyme (recombinant) blends that can be
used on all available donor pancreases.72,73 Research should
also continue into the selective inhibition of the activated
pancreatic enzymes. In parallel, alternative, nonenzymatic
technologies for cell separation, for example, photodynamic
technologies, and so on, should be investigated.74,75
Islet Preconditioning and Culture
The introduction of a pretransplant period of islet culture
has been hugely beneficial from a logistical (patient work-up,
radiology, and so on), physiological (islet recovery, and so
on), and regulatory (functional and safety release criteria) per-
spectives. However, this period of islet culture also pre-
sents an opportunity for novel interventions before islet
implantation which could provide exciting opportunities
to improve clinical outcomes. Potential strategies include
coating with compounds that promote oxygenation and
islet engraftment,76 compounds that reduce instant blood-
mediated inflammatory reaction (IBMIR),77,78 compounds
that enable “in vivo” islet imaging,79,80 compounds that se-
crete local immunosuppression,81,82 and compounds induc-
ing protection against hypoxic stress.83 These approaches
are collectively termed “islet preconditioning” and clearly re-
quire close collaborations with those in the fields of nano-
technology and tissue engineering. The role of peri-islet
“scaffolds” is another area needing extensive research, with
exploration of the associated issues of islet-exocrine inter-
actions, for example, paracrine influences, signaling, and
so on.84-86 Moving such developments through regula-
tory agencies is likely to be complex, because they involve
cellular products, devices, and drugs. The issue of commer-
cialization of human cells is also problematic. Scientific in-
ternational organizations, such as IPITA and TTS, together
with patient advocate groups should engage in facilitating
discussions with regulatory bodies to make these develop-
ments possible.
Defining the Islet Product
The current approach to establishing identity, potency,
and purity of manufactured islet remains crude and vari-
able between centers. Indeed, there is currently no basis
for predicting clinical outcomes based on product charac-
terization. Improvedmeasureswould facilitatemore stringent
release criteria as well as enabling meaningful comparisons
between centers and for the purposes of rigorous scientific
studies.87
Strategies to Stratify Recipient in Terms of High Risk
Versus Low Risk for Islet Survival/Function
The development and implementation of reliable and accu-
rate methods to stratify recipients according to pretransplant
predictors of high risk versus low risk for islet survival/islet
function (eg, immunologic and metabolic signatures)88 should
enable a personalized approach to the optimization of clinical
outcomes after islet transplantation.
Novel Sites for Implantation
Although the liver is easily accessible and has a number
of advantages compared with some other anatomical sites,
it is probably not the “ideal site” for islet implantation. Re-
search should continue to focus on identifying alternative
implantation sites89 which will ensure that islet transplanta-
tion remains a straightforward, well-tolerated, minimally
invasive procedure, but that ensures improved islet graft
survival and optimal glycemic control.
“In Vivo” Islet Imaging and Biomarkers for Islet
Survival and Rejection
The development and implementation of reliable and ac-
curate methods for “in vivo” islet imaging90-92 is essential to
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obtain a better understanding of clinical outcomes, that is,
islet engraftment, the gradual loss of function, evaluation
of the optimal site, and technique for implantation. In addi-
tion, identification of a panel of validated biomarkers
within the blood would greatly enhance our understanding
of islet graft function.
Strategies to Minimize the Need for Systemic Nonspecific
Immunosuppression and Eventually Induce Tolerance
Several approaches are supported by strong preclinical
results and are close to being introduced in clinical studies.
Approaches currently being introduced in clinical studies in-
clude93: cotransplantation of mesenchymal stem cells (MSCs)
or Treg cell; islet pretreatment (anti-HMGB1, islet transduction
to facilitate engraftment, and inflammation); islet encapsula-
tion (both macroencapsulation and microencapsulation—see
below); recipient treatment using nondepleting monoclonal
antibodies (mAbs). Efficient modalities found in experimen-
tal studies should be appropriately applied to preclinical
study. The obviation of immunosuppression would be the
quantum step required to enable islet allotransplantation
to be implemented in younger patients, including children.
It must be remembered that this remains the ultimate aim
of islet transplantation.
Summary of Research Priorities
(1) Optimization of pancreas procurement, pancreas trans-
port, and development of targeted methods for islet iso-
lation to improve functional islet yield to permit routine
single-donor insulin independence
(2) Standardization of definition of released islet product to
enable accurate comparisons between centers and enable
accurate prediction of islet graft outcome.
(3) Development of novel strategies for islet preconditioning
to improve islet engraftment and islet graft longevity.
(4) Definition of suitable alternative anatomical sites for islet
implantation.
(5) Strategies to minimize or eliminate the need for immuno-
suppression, enabling the ultimate goal of islet allotrans-
plantation to be reached, that is, the transplantation
of children
ISLET XENOTRANSPLANTATION
Current State of the Field
Progress made in human islet transplantation in the past
15 years has made commonplace the restoration of near-
normoglycemia, insulin independence, and protection from
severe hypoglycemia with a low risk of procedural compli-
cations in immunosuppressed T1D recipients.49 These fa-
vorable outcomes can now be achieved in single-donor islet
transplant recipients, both with refined induction therapy94
and calcineurin inhibitor-sparing maintenance immunosup-
pression.95,96 Increasing evidence indicates that insulin
independence can be maintained in more than 50% of re-
cipients for 5 years50 and that islet transplants have slow
progression of microvascular complications.97
Improving human islet allotransplant efficacy and safety
outcomes have inspired investigators to develop more widely
available cell-based diabetes therapies. Preclinical safety and
efficacy data obtained in the last 10 years in the stringent
pig-to-nonhuman primate (NHP) islet transplant setting,98-109
and preliminary safety data obtained in recent pilot clini-
cal trials,110 suggest that xenogeneic pig islets can possibly
be developed into an islet β-cell replacement therapy
with broad applicability. However, several hurdles remain to
be overcome.
In the preclinical pig-to-NHP model (Table 1), several
groups have achieved insulin independence for longer than
180 days with near-physiologic control of fasted and post-
prandial glucose in a small number of NHP after porcine
islet xenotransplantation.98-103,106-109 Except for 1 report101
that demonstrated long-term survival of embryonic porcine
pancreatic tissue transplanted to the omentum of 2 monkeys
immunosuppressed with anti-thymocyte globulin (ATG), anti-
IL-2R, anti-CD20, belatacept, everolimus, and FTY720, in all
other studies that achieved long-term diabetes reversal, adult
islets or neonatal islet cell clusters (NICC) were transplanted
intraportally into monkeys in whom the rejection prophylaxis
involved induction or both induction and maintenance im-
munosuppression with CD40-CD154 costimulation path-
way blocking antibodies. Although several studies show the
efficacy of anti-CD154 antibodies in preventing islet xenograft
rejection,98-100,103,106,107 1 report indicates that prolonged
islet xenograft survival can also be achieved with antagonis-
tic anti-CD40 antibodies.102
Genetic engineering of donor pigs mitigates the IBMIR
to intraportally transplanted pig islets.103,111 The IBMIR
is a major obstacle to engraftment of intraportal porcine
islet xenografts in primates112; it is triggered by the con-
tact of isolated islets with blood and causes islet destruc-
tion by complement and coagulation activation products
and other inflammatory mediators released by recruited neu-
trophils and monocytes.113-116 Intraportal transplantation of
galactose-α 1,3-galactose (αGal)-deficient NICC from galac-
tosyl transferase knockout (GT-KO) donor pigs117 increased
achievement of insulin independence in rhesus macaques
when directly compared with wild-type (WT) NICC.103
The improved engraftment of αGal-deficient NICC was
likely due to reduced antibody and complement binding
as well as complement-dependent destruction. Profound
IBMIR was also triggered by WT NICC in baboons, with
intravascular clotting and graft destruction occurring within
hours.111 In contrast, and without directly targeting coagula-
tion, IBMIRwas minimal, and intravascular clotting was not
observed in baboons after transplantation of NICC from
αGal-deficient porcine donors transgenic for the human
complement regulators CD55 and CD59. The extent that
the transgenes CD55 and CD59 contributed to the protec-
tion of αGal-deficient NICC from IBMIR was not directly
addressed. The transgenic expression on adult porcine islets
of human CD46, another complement regulatory factor,
had little impact on IBMIR but was effective in limiting
antibody-mediated rejection.100
There is no additional evidence, as of now, of prolonged
survival of GMporcine islets inNHP.118Xenografts ofαGal-
deficient NICC in NHP were not protected from eventual
cellular rejection.103 Also, αGal-deficient NICC transgenic
for hCD55 and hCD59 underwent cell-mediated rejection
within 1 month after transplantation into baboons immuno-
suppressed with a costimulation blockade-sparing protocol,
including ATG, tacrolimus, and MMF.111 The NICC with is-
letβ cell–specific expression of LEA29Y, a high-affinity variant
© 2016 Wolters Kluwer Bartlett et al S11
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of the T-cell costimulation inhibitor, CTLA4-Ig, were protected
from cell-mediated rejection in humanizedmice.119 Adult por-
cine islets with expression of CTLA4-Ig, under the control
of the porcine insulin gene promoter, have recently been
transplanted into NHP; however, the study was not de-
signed to test the immune-protective characteristics of the
CTLA4-Ig transgene.107
Encapsulation facilitated restoration of insulin indepen-
dence longer than 180 days in 3 porcine-to-NHP islet trans-
plant studies. Intraperitoneal transplantation of adult pig
islets in alginate-polylysine-alginate microcapsules rendered
7 of 9 spontaneously diabetic monkeys insulin-independent
for periods ranging from 120 to 804 days with FBG levels
in the near-normoglycemic range.120 Macroencapsulation
of adult porcine islets in alginate and transplantation into
abdominal subcutaneous tissue as an islet monolayer on
an acellular collagen matrix in a macrodevice maintained
FBG levels less than 150 mg/dL for 20 to 28 weeks in 5
streptozotocin-diabetic, nonimmunosuppressed cynomol-
gus monkeys; 2 of the 4 control monkeys that received
microencapsulated adult porcine islets under the kidney
capsule showed FBG levels less than 150 mg/dL for up
to 2 weeks.108 A subsequent report by the same investiga-
tors showed that coencapsulation of islets with MSCs
slightly improved oxygenation and neoangiogenesis of
subcutaneously placed implants and maintained FBG levels
in the near-normal range for up to 32 weeks in non-
immunosuppressed monkeys; however, the cotransplanted
MSC did not substantially improve or prolong islet xeno-
graft function.109
The first clinical trial of porcine islet xenotransplanta-
tion under a comprehensive regulatory framework was
performed in New Zealand after the authorization by
the Minister of Health under a specific section of the
New Zealand Medicines Act, and also after thorough re-
view performed by the New Zealand Medicines and
Medical Devices Safety Authority, Medsafe, in consultation
with the National Health Research Council and interna-
tional referees.110,121,122 This open label, safety, and dose
finding phase I/IIa study of microencapsulated neonatal
porcine islets, prepared under GMP from designated
pathogen-free donor animals and transplanted intraperito-
neally in 14 nonimmunosuppressed subjects with unstable
T1D, demonstrated the microbiological safety of the tested
encapsulated porcine islet product.123 There was no apparent
dose effect of porcine islets, and porcine C-peptide was not
measurable in the serum of any of the transplanted sub-
jects.110 Nevertheless, the reduced frequency of unaware
hypoglycemic events, the lower HbA1c levels, and the up
to 30% lower daily insulin requirements observed in some
of the subjects posttransplant provided indirect and prelimi-
nary evidence of islet xenograft function.110,122 The same
encapsulated porcine islet product was subsequently tested
at doses of 5000 IE/kg and 10 000 IE/kg in a phase IIa
efficacy trial in 8 subjects with T1D and hypoglycemia
unawareness in Argentina with authorization by the
Minister of Health and approval by the local bioethical
committee.122 This trial confirmed the microbiological
safety of the porcine islet product and demonstrated
lower insulin requirements, frequency of unaware hypo-
glycemic events, and HbA1c levels in most subjects com-
pared with pretransplant.
Obstacles to Application of This Therapy
Although substantial progress has been made in islet xe-
notransplantation, 2 significant obstacles to clinical appli-
cation remain.
First, a clinically applicable immunosuppressive protocol
for preventing rejection of porcine islet xenografts is currently
not available.118 Regimens that protect islet allografts in NHP
and humans from rejection, including basiliximab combined
with FTY720 and everolimus124 and antithymocyte globulin
combined with tacrolimus and mycophenolate mofetil,125 fail
to facilitate long-term islet xenograft survival in NHPs,98,111
indicating that either the immunity to islet xenografts is
stronger than islet allografts or that additional immune rec-
ognition and effector pathways are operative in xenoislet com-
pared with alloislet transplantation. As summarized above,
prolonged porcine islet xenograft survival has been achieved
with protocols based on CD154-CD40 costimulatory block-
ade by several groups. However, long-term functional survival
exceeding 180 days, the efficacy milestone to be met in 5 or
more of 8 NHP before initiating clinical trials according to
the consensus statement of the International Xenotransplan-
tation Association,126,127 has been demonstrated in only
a small proportion of transplanted NHPs (1 to 2 of 3 to
7 in several studied cohorts; Table 1).
Lack of more consistent success could be ascribed to fail-
ure of the protocol to prevent rejection or to failure of the pre-
clinical model to accommodate the protocol.128 Therefore,
continued understanding and improvement of the preclinical
animal model is a critical requirement for documenting long-
term success on a consistent basis.
Long-term success has also been precluded by a high
proportion of engraftment failure after porcine islet trans-
plantation due to IBMIR and complement-mediated lysis
of islets triggered by binding of preformed xenoreactive an-
tibodies. Engraftment of neonatal porcine islets has recently
improved considerably with the use of GT-KO donors.103,111
Early posttransplant loss of adult islets from GT-KO can be
very significant,107 possibly due to the activation of comple-
ment by transplanted islets via the alternative pathway.106 As
shown in human islet allotransplantation,50,129 increasing the
proportion of transplanted porcine islets that stably engraft
will substantially improve long-term islet graft function.
Several immunotherapeutics with demonstrated efficacy in
inhibiting immune responses to porcine islet xenografts are
no longer available for clinical investigation in transplanta-
tion due to their safety profile. These include in particular
anti-CD154 antibodies and also FTY720, anti-LFA-1 anti-
bodies, and LFA-3-Ig. Alternative strategies, such as antago-
nistic anti-CD40 antibodies, are being investigated; however,
none of these investigational antibodies will be available for
clinical research in islet xenotransplantation in the very fore-
seeable future.
The risks of immunotherapeutic protocols being devel-
oped for initial pilot clinical trials must not be higher than
the risks associated with immunosuppression currently used
clinically in organ and islet allotransplantation. For islet xe-
notransplantation to be applied very broadly in the future,
a rejection prophylaxis with a very favorable safety profile
will be required. It is reasonable to assume that immunother-
apeutic protocols will become increasinglymore selective and
safe as our understanding of the immunobiology of islet xe-
notransplantation improves.
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The second major obstacle to broader clinical application
of islet xenotransplantation is the high number of designated
pathogen-free donor pancreases required for manufacturing
a therapeutic patient dose of neonatal porcine and adult pig
islets. The minimum number of nonencapsulated pig islets
transplanted to achieve normoglycemia in NHP has been
50 000 IEQ/kg or greater for neonatal islets99,102,103 and
25 000 IEQ/kg or greater for adult islets,98 though much
greater numbers have been transplanted in some stud-
ies.100,106,107 Fewer porcine IEQ are expected to be required
per kg body weight of human recipients, whose insulin re-
quirements per kg are 2- to 3-fold lower compared with
streptozotocin-diabetic monkeys.128,130 The exact number
of porcine islets required to restore insulin independence in
humans with T1D remains uncertain, but assuming a yield
of 400 000 IEQ from a good adult porcine pancreas,131
3 or more suitable adult pancreases would be required
for 1 patient dose. Manufacturing of NICC is much less
challenging and costly and islets from neonatal pigs main-
tain a proliferative capacity after transplantation; however,
the number of donor pancreases expected to be required
per patient dose with commonly used techniques132 is con-
siderable. Further improvements in the selection of suitable
source pigs and in porcine islet manufacturing will need to
be achieved to develop commercially viable adult and of neo-
natal porcine islet therapy products.
Housing of designated pathogen-free pigs under strict bar-
rier conditions will require significant resources. As the islets
will be isolated and cultured, likely for several days, testing
of the islets alone (ie, the ‘product’) for the presence of mi-
croorganisms should be sufficient to ensure that no bacte-
ria and fungi will be transmitted, although monitoring of
the herd will be required to ensure no viruses are pres-
ent.133-135 The requirement of designated pathogen-free
porcine donors may therefore not be as stringent for islets
compared with organ xenotransplantation. Inevitably,
porcine endogenous retroviruses (PERV)will be transplanted
with the islets.136 However, monitoring of humans exposed to
various pig tissues and cells has never identified active PERV
replication.137-140 Although national regulatory authorities,
for example, the Food and Drug Administration in the
United States, will insist on monitoring for PERV, clinical
xenotransplantation is unlikely to be precluded on the basis
of the presence of PERV alone.141 Furthermore, if essential,
techniques of small interfering RNA could successfully pre-
vent PERVactivation after transplantation.142
The Research Agenda
The research agenda in nonencapsulated islet xenotrans-
plantation focuses on meeting the key requirements for initi-
ating pilot clinical trials, that is, prevention of IBMIR and
prevention of cell-mediated rejection with anti-CD154 spar-
ing and clinically applicable immunosuppression.
The IBMIR is a multifaceted process involving coagu-
lation, complement activation, cytokine and chemokine re-
lease, and granulocytes/monocyte infiltration.115,116 Many
different strategies have been investigated. Targeting coagu-
lation using low-molecular weight dextran sulfate alone114
and in combination with tissue factor pathway inhibitor-
transgenic islets,107 and thrombomodulin111 has at best
mitigated but not prevented IBMIR in preclinical islet xeno-
transplantation. Strikingly, the use of neonatal islets from
GT-KO porcine donors has been more successful,103,111
pointing to the importance of complement activation via
the classical pathway caused by binding of preformed xeno-
reactive antibodies to islets. It is probable that preformed
antibody binding to other (ie, nonGal) antigens will also
be an initiating factor in complement activation after por-
cine islet transplantation in humans. To date, the identity
of nonGal antigens on porcine islets has not been fully deter-
mined. N-glycolylneuraminic acid is likely to be a target in
clinical islet xenotransplantation, though this oligosaccha-
ride is not important in pig-to-NHP islet transplantation
because NHP also express it and therefore do not produce
natural antibodies against it.143 Pigs that express neither Gal
nor N-glycolylneuraminic acid are now available for preclini-
cal research.144 Recent evidence demonstrated the contribu-
tion of the alternative complement pathway to IBMIR
and the mitigation of early loss of adult porcine islets in
NHP treated with human factor H.106 In view of increasing
evidence indicating the activation of classical and alternative
complement pathways, complement-specific biologics, such
as compstatin that inhibit both pathways appear to be prom-
ising interventions.116,145
For the control of inflammatory cytokines/chemokine
axis, biological drugs, such as anti-TNF-α mAb (humira and
infliximab), TNF receptor-Ig fusion protein (sTNFR, etanercept),
and IL-1β receptor antagonist (anakinra) are available for
off-label use.146 Finally, the CXCR1/2 allosteric inhibitor,
reparixin, has been shown to inhibit the infiltration of neu-
trophils into islet grafts in experimental and clinical islet
allotransplantation.147,148
An alternative approach to preventing IBMIR would be to
place the islets in a site where they are not immediately ex-
posed to blood. The gastric submucosal space has the advan-
tage of being accessible by endoscopy,149,150 and endoscopic
biopsy of the graft may be possible.150Other sites are also be-
ing explored.151-153
Taken together, because the IBMIR is a multifaceted
phenomenon, the combination of interventions targeting
coagulation, complement activation, and recruitment of
neutrophils andmonocyteswill be required to ameliorate early
graft loss and prolong the graft survival in porcine-to-human
islet xenotransplantation.
Anti-CD154 antibody-based immunosuppressive protocols
achieved long-term survival of WT and genetically modified
porcine islets in several NHPs. For the clinical translation of
this immunosuppressive protocol, the replacement of anti-
CD154 mAb is required due to its associated risk of throm-
boembolic events.154 Preventing cell mediated rejection of
porcine islets using anti-CD154 antibody-sparing protocols
will likely require detailed immune mechanistic studies to
determine the precise immune recognition and effector path-
ways inhibited by anti-CD154 immunotherapy in the above-
referenced studies.
Induction therapywith anti-IL2RmAb andmaintenance im-
munosuppression with tacrolimus, sirolimus, and CTLA4-Ig)
prevented adult porcine islet xenograft survival on a very consis-
tent basis in a large cohort of monkeys; however, diabetogenic
and other side effects associated with this protocol prompted
the investigators not to consider clinical development of this
protocol (Graham ML and Hering BJ; unpublished).
Whether antagonistic anti-CD40 mAb can substitute for
anti-CD154 mAb in preventing islet xenograft rejection is
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currently unknown, it is conceivable that anti-CD40 mAbs
are less effective than anti-CD154 mAbs because they fail
to mediate Fc-dependent depletion of activated T cells,155
and they fail to block the interaction of CD154+ T cells
with monocytes, macrophages, and neutrophils expressing
the integrin Mac-1 as an alternative pathway for CD154-
mediated inflammation.156 To date, the efficacy of only 1
antagonistic anti-CD40 mAb in preventing porcine islet
xenograft rejection in NHP has been reported.102 Currently
available antagonistic anti-CD40mAbs proven to be effective
in islet allotransplant models include chi220,157 3A8,158
2C10R4,159 and ASKP1240 (4D11).160 The replacement of
anti-CD154mAbwithanti-CD40inaprotocolwhichachieved
long-term islet xenograft graft survival in NHP using ATG
induction combined with anti-CD154 mAb and sirolimus
maintenance failed to show similar efficacy (Park CG et al,
unpublished).
Additional studies exploring the efficacy and mecha-
nisms of action of presumably more potent antagonistic
anti-CD40 mAb, such as 2C10R4 and ASKP1240, used for
induction and maintenance therapy alone and in combina-
tion with other immunotherapeutics remain to be performed.
We suggest, therefore, that an anti-CD40mAb–based regi-
menwill prove effective when neonatal islets from genetically
engineered pigs are transplanted. Anti-CD40mAb-based
regimens have shown efficacy in xenotransplantation of hearts
and kidneys from genetically engineered (eg, GT-KO/CD46)
pigs in baboons.161,162 Accordingly, future studies of anti-
CD40 mAb should also address the survival of islets from
genetically modified donors.
Additional immune intervention can be harnessed, such
as negative vaccination using ethylenecarbodiimide-fixed
donor apoptotic cells163 and thymus cotransplantation164
to reduce the immune response or induce tolerance against
xenoantigens. Pig islet transplantation may be enhanced
by the cotransplantation of mesenchymal stem cells (of
either recipient or donor origin)165,166 or donor Sertoli
cells.167,168 Both cell types may facilitate revascularization
of the islets, reduce the inflammatory response, and pro-
vide immunoprotection.
What Is the Potential for the Treatment of Diabetes?
A number of key requirements for performing additional
clinical trials of porcine islet products have already been
met. First, the regulatory framework established by national
health authorities (including but not limited to the US FDA
and EuropeanMedicines Evaluation Agency) and the recom-
mendations made by International Xenotransplantation As-
sociation and the World Health Organization provide a safe
and suitable framework for conducting clinical trials of inves-
tigational porcine islet products in T1D. Second, a surveil-
lance and safety program has been developed to detect,
measure, manage, report, and respond to infectious diseases
caused by known infectious agents and, possibly, previously
unknown or unexpected pathogens in individual recipients
of pig tissues. Finally, suitable, designated pathogen-free,
WTsource pigs have been generated for planned pilot clinical
trials. However, other key requirements remain to be met, in-
cluding first and foremost the development of a safe and con-
sistently effective rejection prophylaxis and the development
of a commercially viable porcine islet product. Accordingly,
the significance of islet xenotransplantation in the care of
patients with diabetes in the next 10 years will be determined
by progress made in these 2 areas. Equally important in the
determination of the future significance of islet xenotrans-
plantation will be the progress made in the development of
the AP and stem cell-derived sources of islet cells.
Summary of Research Priorities
(1) Prevention of IBMIR. This will likely require a multi-
faceted approach including targeting coagulation,
compliment, inflammatory cytokines/chemokines and
granulocytes-monocytes.
2. Development of effective and clinically acceptable antirejec-
tion regimens. An important current focus is on the targeting
CD40-CD40L interactions with anti-CD40 antibodies.
ISLET ENCAPSULATION—AN ONGOING
DEVELOPMENT CHALLENGE
Current State of the Field
Over 40 years of islet encapsulation research has failed to
provide an approved clinical product despite many encapsu-
lation approaches and efforts, including several clinical trials.
This IPITA effort is critical to focus on future research goals
and objectives that have the promise to achieve a successful
clinical encapsulated islet product in as short a time as possi-
ble. A major review of encapsulated islet efforts has recently
been published which describes the history and accomplish-
ments of research and development of islet encapsulation as
part of an Advanced Drug Delivery Reviews issue entitled
“Cell Encapsulation and Drug Delivery.”169,170 There have
been 2 major types of encapsulating devices: macrodevices
and microencapsulation.
Macrodevices
Macrodevices seek to confine the total transplanted cell
volume within a single, confined device. The appeal of this
approach is that the implant is easily transplanted and re-
trieved. The primary challenge of this approach, however, is
that, when avascular, it is plagued with inefficient nutrient
and product delivery.
Early Extravascular Diffusion Devices
The origin of these extravascular diffusion devices began
with the work of Algire, Prehn, and Weaver (1948-1959)
who originated a planar diffusion device for the purpose of
studying the mechanisms of immune rejection of cells and tis-
sues. In the process of their successful research, they defined
membrane biocompatibility, host cell membrane overgrowth,
delays in immune rejection of encapsulated tissues, and pre-
vention of allograft rejection, but not xenograft rejection.
After the development of hollow fiber technology for renal di-
alysis, Amicon hollow fibers became the target of inserting is-
lets inside to use as diffusion devices. The majority of these
studies were performed byWm.Chickwho reported that their
long-term results were limited by host membrane overgrowth.
However, this problem for hollow fibers was overcome by
the use by the cytotherapeutics team of tubular devices with
alteredmembranematerials in 1985 to 1995 that enabled en-
capsulated islet implant success in rodent models. A non-
curative clinical trial was published with subcutaneous
implants of this device in 3 types of human recipients:
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nondiabetic, T1D, and T2D. This study demonstrated the re-
covery of viable and functional human islets after several
weeks of implanted islet allografts. However, the low pack-
ing density reduced the clinical interest in this device type
due to the large volume of encapsulated islet hollow fibers
that would have been required for a curative clinical trial.
Because this trial was performed without the use of immu-
nosuppression, it is important to note that 2 of the 9 recip-
ients developed donor antigen sensitization. This is a
potential risk for diabetic patients receiving encapsulated
islets without immunosuppression because this could in-
crease their risk of a positive crossmatch if they ever re-
quired a kidney transplant.
Current Extravascular Diffusion Devices
The next device approach returned to a planar device design
by BaxterHealthcare in the early 1990s to develop a device for
their future gene therapy products. It was a well-designed flat
sheet device with a central islet chamber and a tubular loading
port. Although it workedwell in rodents, once an alginatema-
trix was used to prevent cell clumping and necrosis, results in
large animals showed less robust capillary ingrowth in the
outer walls of the polyester outer coat. It became known as
the Theracyte device after it was sold by Baxter to Theracyte.
Currently, this device type is the first choice for 2 compa-
nies looking for a diffusion device to encapsulate human
embryonic stem cell (hESC)–derived islets that will assure
these cells cannot escape from the device. Both companies,
Viacyte and Betalogics, are making separate modifications to
this device type to meet their needs for this newly developed
insulin-producing cell (IPC) source.
Current Direct Oxygenation of Extravascular
Diffusion Device
Reviews of many results of encapsulated islet implants re-
veal that the major acute cause of encapsulated islet death is
hypoxia. It takes too long for new capillary development
and ingrowth to keep the freshly implanted, encapsulated
oxygen-requiring islets from dying. Since 2005, βO2 has been
developingmanyways to provide direct oxygen delivery to the
encapsulated islets through peripheral connections to their im-
planted device. These β-O2 studies have been successful in ro-
dents and more recently in large animals. The first individual
patient trial for this device showed persistent islet graft function
in the chamber for 10 months with regulated insulin secretion
and preserved islet morphology without immunosuppres-
sion.171 Ongoing clinical trials are planned for the near future.
Intravascular Diffusion Device
In the 1980s and 1990s, the WR Grace company joined
in a research venture with Biohybrid to develop an intra-
vascular device to eliminate the acute loss of islet mass from
hypoxia as well as continuously supply oxygen to the func-
tional encapsulated islets. After many designs, they devel-
oped the “Hockey Puck” device that perfused arterial
blood flow through tubing around which the islets were
implanted within the device. This device demonstrated
the longest duration of efficacy for a macrodevice both
with islet allografts and xenografts in diabetic dog recipi-
ents to date. The FDAwas reviewing the potential to initi-
ate clinical trials with this device when disaster struck this
model by the unexpected disconnection of the carotid ar-
tery cannulae to the device resulting in exsanguination of
the diabetes-cured canine recipients. This complication
closed the program, and except for a few repeats with dif-
ferent approaches, this type of device has not continued
forward for any clinical applications.
Intravascular Ultrafiltration Device
Although a limited number of investigators have tried this
approach, the concept is excellent for the islets because it not
only provides continuous oxygenation to the islets but also
eliminates the problems of diffusion of insulin from the de-
vice. Even though the in vitro results were excellent and the
early rodent in vivo results were promising, this lead has
not been followed since the 1980s.
Microdevices
Alginate Microcapsules as Islet Diffusion Devices
Alginate and similar hydrogels that formed into microcap-
sules have produced hundreds of publications with multiple
successes in rodent models of diabetes, but remain with limi-
tations for achieving significance for large animals and hu-
man clinical trials. The standard islet encapsulating alginate
microcapsules are produced by droplets of sodium alginate
mixed with islets into a bath of CaCl2 or BaCl2 that rapidly
crosslinks to form the capsule containing the islet. Standard
alginate microcapsules are 500 to 1000 microns in diameter
with a significant percentage of the capsules not containing
islets. Because gravity pulls on the islet with its higher density
than the alginate during the drop formation and falling,
many of the islets tend to sink within the droplet so when it
is cross-linked, a portion of the islets is on the edge of the cap-
sule, not adequately protected from immune attack. These
large capsules have a very small percentage of their volume
as islet so a potential clinical dose of alginate-encapsulated is-
lets is very large, even for the peritoneal cavity. Multiple
methods have been developed to make the alginate capsules
smaller by reducing the surface tension of the droplet,
such as vibrating the droplet needle or using an air knife.
Connecting the needle with direct current to the calcium
bath provides an electrostatic condition that also results
in smaller capsules. However, all of these methods to
make smaller alginate capsules by reducing the surface
tension should be replaced with the more recent methods
of making small capsules by the use of microfluidics. An-
other basic problem is that the pore size is very open so
that a second layer of polyamine or similar substances
are coated on the surface. However, because this second
coat makes the biocompatibility worse, a third coat of algi-
nate is required. The vast majority of published encapsulated
islet results use alginate-encapsulated islets. They have
been implanted successfully in rodents, to a lesser degree
in large animals as well as humans. Currently, Living Cell
Technologies has been conducting clinical trials of alginate-
encapsulated porcine islet transplantation in different coun-
tries with several collaborators. Ongoing results have not
yet achieved the degree of success desired.110
Alginate Alternatives
To address these problems, investigators have been work-
ing on making Minimal Volume Capsules of alginate as
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demonstrated most successfully by the Calafiore group.
Other modifications are to replace alginate with agarose as
was done by Iwata's group. Due to slower crosslinking,
they moved to an emulsion approach that results in cen-
tered islets with smaller capsule volumes. Although these
results appeared promising in rodents, this approach has
not been picked up by other groups. Taylor Wang has de-
veloped multicomponent islet coatings that also center the is-
let and have shown good results in rodents. Large animal
studies appear promising for this unique microcapsule.
PEG Conformal Coatings
Jeff Hubbell working with Novocell developed an interfa-
cial polymerization formed by radicals that causes a thin
coating of poly(ethylene) glycol (PEG) to form on the surface
of each islet outward to a desired thickness. Rodent implants
were excellent, but failed in translation to large animals due
to bioincompatible reactions and islet losses that required de-
velopment of new forms of PEG that were biocompatible.
The PEG-coated baboon islets were successfully implanted
subcutaneously into diabetic baboons with normoglycemia
maintained up to 2 years without immunosuppression or
insulin. A GLP study in diabetic baboons was performed,
successfully leading to the approval of a ;phase I/II clinical
trial in T1D recipients. However, when only partial func-
tion was achieved in the first 2 recipients, the trials were
closed. This PEG technology has been taken to a second
generation by Hubbell who is now collaborating with
Converge, a biotech start up in collaboration with the Di-
abetes Research Institute with early rodent and large ani-
mal results that are promising.
Nanoscale or Layer-by-Layer Islet Coatings
The Iwata group has been developing even thinner islet
coatings with different materials, such as PEG-lipid coatings
with poly(vinyl alcohol) alginate up to 10 layers thick on
each islet with early promising rodent results. More recently,
they are trying to place layers of living cells, such as
chondrocytes on the surface of islets, to protect them from
immune destruction.
Novel Thermoreversible Islet Coatings From a
Glucose Polymer
Alex Gorkovenko has produced a novel polymer of glucose
that is a thermal-responsive gel that is both biocompatible and
has programmable biodegradability. In collaboration with
Prodo Labs, a new islet encapsulation technology is being
developed with encapsulated islet size peaking at 250 mi-
crons and centralization of the islets with few empties. In
vitro studies show excellent glucose-stimulated insulin re-
lease results with initial implants into diabetic mice show-
ing graft function.
Corporate Involvement in the Development of
Islet Encapsulation
From 1980 to current, there have been over 40 corpora-
tions involved in developing encapsulated islets into a clin-
ical product. The companies range in size from small startups
to large corporations, such as Baxter, Amicon, WR Grace,
Metabolex, Gore Medical, and Johnson& Johnson. The
specifics of these efforts are documented in the Advanced
Drug Delivery Reviews article.170 There are currently 11
corporations actively involved developing islet encapsu-
lation technology.
The Research Agenda
With a vision to translating islet encapsulation to the clinic
within a short timeline (5 years), the goals are modest, with
the convergence of a short-course immunosuppressive ther-
apy and a focus on allogeneic islet sources. Once the potential
of microencapsulation as a strong tool for mitigating immu-
nological attack is demonstrated, broader goals seeking to
expand the cell source and/or eliminate immunosuppression
completely can be explored.
Alginate Encapsulated Human Islets With
Modest Immunosuppression
Because of the ongoing problems with alginate encapsu-
lation, a minimum volume capsule with modest immuno-
suppression should be targeted as a likely candidate to
demonstrate clinical efficacy within this time frame. Previ-
ous approaches sought to gain it all without the use of im-
munosuppression. A first step to the clinic would be to
define a minimal immunosuppression approach that per-
mits islet graft function while reducing the burden of
totally relying on the coating to protect the encapsulated
islets. Given what limited information is known about
the capacity of encapsulation to mitigate immune rejection
in a patient that will express both alloimmunological and
autoimmunological responses, the first step to the clinic
would be to combine either low-dose or short-course im-
munotherapy with encapsulation to define if this combina-
tion could have a synergistic effect. Yet, thisminimal approach
may create new problems if the alginate coating is too large
to implant into the portal vein. Even if it is sufficiently
small for the implants, it brings the additional burden of al-
ginate bulk in the portal vein with repeated implants. This
research would require minimal volume capsules because
allogeneic islets are initiated in diabetic large animals to
determine the risks and benefits before implanting into di-
abetic humans. Although previous clinical trials used the
intraperitoneal site, the optimal encapsulated islet implant
site needs to continue as a research target.
Screening New Biomaterials With Low Innate Immune
Activation Propensity
The current alginate/agarose polymers suffer from the
lack of specific control properties and purification. Several
new and unique biomaterials are becoming available which
can better meet these requirements and should bemoved rap-
idly to large animal studies once biocompatibility is demon-
strated for each candidate.
Nonalginate New Polymers
Several of these new polymers under development need
to be tested for biocompatibility and toxicity with islets
followed by islet functional testing. If these are minimal, they
need to be fast tracked into islet functional testing and im-
planted. Some of these include Alginate-N3 hydrogel, extra-
cellular matrix microspheres, and extracellular motifs.
Microfabrication Approaches to Decrease Capsule Sizes:
Many of these choices can result in smaller capsule sizes
© 2016 Wolters Kluwer Bartlett et al S17
increasing nutrient/waste diffusion and functional respon-
siveness as well as be more amenable to intrahepatic sites.
Bioactive Polymers to Enhance Vascularization
and Engraftment
These include known items such as vascular endothelial
growth factor or other methods of encouraging rapid new
vessel formation at the time of implant. It also could include
methods of prevascularization of devices to establish a vascu-
lar response before implanting the islets within the device, if it
can be loaded after implant. It also could include the incorpo-
ration of VEGF or other stimulants of new vessel growth
within the device that are designed to elute from the device
for a period.
Combination of Encapsulation and
Local Immunosuppression
The use of systemic immunosuppression is to be avoided
if possible. However, localized immunosuppression adja-
cent to or from within the encapsulating device may be suf-
ficient to protect the islets. Polymers could be used to provide
controlled release for local immunosuppression. This ap-
proach could also include the addition of human MSCs
within the device. Alternatively, the use of a genetically
modified islet source, such as transgenic pigs expressing
LEA294, a high affinity variant of T-cell costimulating in-
hibitor CTLA4-Ig, may provide local immunosuppression
for encapsulated islet transplants.
Alginate Encapsulated Porcine Islets With Full
immunosuppression Either Simultaneous or After
Kidney Transplant
Alginate is insufficient to protect xenograft islets from
immune attack so these devices will always require immu-
nosuppression. The allograft immunosuppression is unable
to protect unencapsulated xenografts but the combination
encapsulation and allograft immunosuppression may be
effective in xenografts. The focus of this approach is to in-
crease the potential donor islet pool using xenografts with-
out excessively increasing immunosuppression over that
needed for allografts.
PEG Encapsulated Human Islets
With Immunosuppression
Although the first-generation PEG patent protection was
abandoned byNovocell, the second-generation PEG technol-
ogy should be tested in humans initially with immunosup-
pression. Although there are different surface modifications
that can reduce inflammation, the safety profile for PEG is
better than alginates. The combination of PEG and immuno-
suppression has been shown to increase early engraftment.
Oxygen Delivering Macrocapsules
Without Immunosuppression
Delivery of oxygen gas into the device is under develop-
ment by βO2 which may shift the primary cause of encap-
sulated islet graft failure from hypoxia to an immune cause.
The clinical proof of principle for macro-oxygenation needs
to be completed. In addition, microencapsulation of perfluo-
rocarbon or oxygen-generating materials has been accom-
plished and need to be considered for these applications
either inside of the islet device or in close proximity.
Key Methodologies Not Being Used
Intravascular Macrodevice Approach
Although this approach may seem too risky as evidenced
by the previous attempts in diabetic dogs, there have been ex-
tensive advances from product development in vascular grafts
and shunts because those studies were completed. A new ap-
proach with modern techniques and shunt materials needs
to be considered. The risk of blood interactions should be re-
duced by new polymers and intravascular device designs.
Combination of Immunosuppression and Encapsulation
(a) Systemic low-dose or altered dose or additional drug—In
the past, encapsulation approaches have typically attempted
an “all or nothing” approach to the use of immunosup-
pressive drugs. As such, limited preclinical, and no clin-
ical, studies have explored the potential synergistic effects
of immunosuppressive reagents and encapsulation. Multi-
ple approaches could be evaluated, such as systemic low
dose/altered dose/alternative drugs. Further, when encap-
sulated islets are placed within alternative sites, avenues
for local delivery of drugs are highly feasible. Drugs could
be eluted from the encapsulation material itself or from
eluting materials placed around the implants.
(b) Local delivery of drugs from encapsulating materials—The
addition of different types of drugs that can be eluted or re-
leased from the encapsulating materials need to be defined
and tested to avoid the systemic complications of immuno-
suppression. This is especially true for treating patients
with diabetes because they need islet replacement to pre-
vent the complications from reaching an end stage rather
than waiting to perform a transplant after the complica-
tions have already done significant damage.
(c) Macrodevice approaches other than theracyte extravascu-
lar device—The design of this device with polyester as its
outside supporting structures makes it very hard to use
without ingrowth of the device into the recipient. Either
coating the polyester or replacing it will increase the value
of this type of device.
(d) Convergence of vascularized implant site with encapsu-
lated islets—Newways of combining these 2 requirements
need to be focused on to develop novel ways of achieving
this goal. Examples include modification of the local envi-
ronment of the device with bioactive surfaces, localized
drug delivery, and in situ oxygen generation. Alternatively,
the site could be prepared before implanting the islets so
oxygenation no longer is a restriction after implant.
(e) Reduced capsule volumes and thickness—The days of
injecting large volume alginate or other types of capsules
need to be over because these large volumes are not clini-
cally relevant. The focus should only be onminimal volume
capsules that can be achieved with different approaches
already defined.
Novel Encapsulation Materials
New Hydrogels
(1) Glucose polymer—This new polymer has many opportu-
nities to be further modified with different types of addi-
tions to the basic structure of the polymer.
(2) Syntheticmaterials—Examine PEGsor other novel hydrogels
or responsive and bioactive materials for islet coating
technologies.
Define the Optimal Biomarkers and Assays for Predicting
Islet Survival and Function and Understanding Causes of
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Failure—The current approaches are often missing mecha-
nistic evaluations that are critically needed to understand
the progress and predict the next studies to be completed.
Areas of Controversy and Impediments
Optimal Implant Site
(a) Unique considerations for encapsulated islets—There is a
need to compare the unencapsulated islet implant require-
ments with the unique requirements for encapsulated islets
for each implant site under consideration. The specific
items below are left in question form for those areas that
have not been firmly established.
(b) Intrahepatic site—There certainly is clinical evidence that
intraportal vein encapsulated islet implants can cause portal
hypertension, liver impairment, hemorrhage, and death, al-
though on a very limited basis. Portal pressures should be
routinely measured during the infusion as is done for
unencapsulated islets. Yet, there are several critical ques-
tions that have not been answered. What is the volume
of encapsulated islets that the human liver can handle for
a single encapsulated islet implant yet avoid portal hyper-
tension? Can the encapsulation material degrade suffi-
ciently fast enough to complete the next implant and still
be protective of the encapsulated islets? What is the time
course over which repeated intraportal encapsulated islet
implants can safely be performed?
(c) Intraperitoneal Site—Because the human pelvis is shaped
as a centrifuge tube when sitting or standing, injected islets
that do not stick to the abdominal tissues fall to the bottom
of the pelvis, compact there, and undergo hypoxic death
rather quickly. Can one make the capsules more sticky to
prevent their dropping to the pelvis while at the same time
not have this increased stickiness lead to capsule fibrosis?
(d) Omental site—The omental site has advantages in that a
variety of pouches can be created that can entrap the islets
that can also lead to vascularization. Yet, will the capsules
stay within the omentum itself and gain vascularization or
does a pouch have to be created to hold them and does vas-
cularization have to be induced?
(e) Intestinal or gastric submucosa site—Encapsulated animal
islets have been injected in both the intestine and gastric
submucosa. Can the encapsulated human islets be injected
into these sites and gain sufficient vascularization without
compromising the integrity of the intestine or stomach
while maintaining long-term functional survival?
(f) Subcutaneous site—The subcutaneous site has shown prom-
ise in animal models. One human study has suggested
that long term insulin injections before encapsulated im-
plants lead to sufficient subcutaneous scarring that insulin
transport away from the implant site is delayed and re-
duced.170 How normal functioning will the encapsulated
islets be in the face of extraportal circulation? How fast
will the insulin delivery out of this site be in the face of
chronic scarring from years of insulin injections? How
severe will the local fibrosis and fat formation become
in these subcutaneous implant sites done in the face of
insulin injection scarring?
Type of Device in Terms of Islet Retrieval
and Replacement
(a) All-in and all-out device type—This device is designed to be
implanted with an islet load and then easily removed
completelywhen the islets need to be replaced. Thus, it can-
not cause the surrounding tissues to grow into the device.
Can such a device be readily removed with the expended
islets and readily replaced without damage to the patient at
that site? Such a curative device may require 200 cm2
surface area as a minimum and perhaps even 2 to 3 times
for a curative response with the required numbers of en-
capsulated islets. What sites are amenable to these require-
ments for this type of device? How will this approach deal
with the immediately postimplant islet hypoxic losses?
(b) Flush and reload device type—This type of device is de-
signed to be permanently implanted into the recipient
and as such requires the ability to flush out the old islets
and reload fresh islets whenever required. When the islets
need to be replaced, what design characteristics are re-
quired to maintain the implanted device within the host
yet still permit effective removal of the expended islets by
simply flushing them out and then loading the new islets
into the implanted device?Howdoes one assure the preven-
tion of encapsulated islets becoming stuck to each other
preventing their flushing?
(c) Combination of all-in/all-out and flush/reload devices—
Experimental designs may require some combination
of these very basic requirements to be successful in read-
ily achieving removal and replacement of islet loads in
these recipients.
Enhanced Oxygenation Requirements
There are 2 problemswith lack of oxygen for encapsulated
islets: (a) immediately after implantation a significant num-
ber of islets die of hypoxia as it takes several days for new
blood vessels to grow and (b) unless islets have sufficient
oxygenation, they cannot maximally produce their required
insulin. So, by definition, any encapsulation system that
chronically limits oxygenation levels of the β cells will
have a marginal outcome.
(a) Acute Postimplant Requirement  2 to 4 Weeks
Direct Oxygen Delivery—β O2 is directly supplying free
oxygen on a regular basis to the encapsulated, implanted is-
lets that will presumably be required for the life of the islets
within this type of device.
VEGF before or acutely with islet—While both approaches
need to be tested, it is clear that VEGF added without any
hypoxic tissue targets will not lead to effective vasculariza-
tion because there is nothing for the new vessels to attach
to, and thus they will disappear. So timing of treating the
device without the islets has to be closely determined. In
addition, adding the VEGF at the time of implant will not
by itself help much because the islets will die off before suf-
ficient quantities of new vessels can grow out.
Vascularization of device before islets—There are other
ways than adding VEGF to the device to grownew vessels be-
fore implanting the islets, such as maintained factor release
over time and others. These need to be explored to see if they
can benefit islets survival.
Devices Containing Microencapsulated Oxygen—
Microencapsulated oxygen is currently available. Yet, it
is not being used because some believe that it will only stay
oxygenated for a few hours after implant that is not long
enough to protect the islets beyond acutely. However, with
the oxygen carrier encapsulated, it cannot escape to the
lungs and will remain in the implant site still binding the
oxygen. When it has released all of its oxygen after im-
plant, one needs to test whether simply breathing 100%
oxygen for several minutes a day will replenish the oxygen
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carrier with sufficient fresh oxygen binding to the carrier
located with the islets to maintain their function.
(b) Chronic Oxygen Requirement
Adequate oxygen availability is required for normal islet
function. With restricted oxygen, the encapsulated islets
may remain viable but cannot function. Easily replenished
chronic oxygen supply with oxygen carriers with islets is
required as long as islet function is required.
Islet Functional Capabilities
Encapsulated versus nonencapsulated islets—For each spe-
cific type of islet encapsulation approach developed, what
limitations on islet function are the result of the encapsula-
tion process, considering both acute and chronic changes?
Duration of effective treatment for a long-term product—
There certainly is a difference in postimplant success for islet
autografts and allografts or xenografts. How efficiently do
the encapsulated islets continue to function at what percent
of their normal capacity both acutely and long term? What
is the functional duration of the encapsulated islets function-
ing at what level of normal responsiveness?
Strategy for islet replacement—To avoid being a simple
demonstration using a fraction of the needed islet mass, a
strategy for islet full replacement by encapsulated islets is re-
quired with current technology in which normoglycemia can
be fully attributed to the encapsulated graft. What are the
criteria for replacement of encapsulated islets? What is the
priority of encapsulated islet recipients to receive additional
doses of islets over those who have not received an islet im-
plant? What is the role of donor sensitization in determining
which patients get the next doses of encapsulated islets in
cases where low or no immunosuppression is required?
Sticky islet coatings—Sticky islet coatings increase the host
response for vascularization but also increase the fibroblast
and immune attack. Is there a method to get just the right
kind of islet coating stickiness? Does host reactivity to the de-
vice reduce over time?
Insulin delivery to portal vein or systemic vein—
Encapsulated islet implants into the portal vein have been
limited by capsule size and breakdown rates. What are
the requirements for islets in terms of long term function
if they deliver insulin through the portal vein or do not?
Does this site of delivery have any effect on delayed func-
tion leading to reactive hypoglycemia?
Speculation of Potential Therapeutic
Utility in 5 to 10 Years
(1) There will be multiple types of encapsulated islet ap-
proaches under clinical trials permitting direct compari-
sons of different types.
(2) Novel methods of required oxygenation of encapsulated
islets will be obtained.
(3) Combination of islet encapsulationwith local immunosup-
pression delivery will greatly reduce risk of systemic immu-
nosuppression expanding procedure from limited kidney
transplant recipients to widespread application.
(4) Successful human islet expansion will reduce the need for
more immune challenging porcine islet xenografts.
(5) Due to these improvements, encapsulated islet therapy
will be expanded to people with significant T2D as well
as meeting demands of people with T1D.
Summary of Research Priorities
(1) Conduct a preliminary trial of alginate encapsulated is-
let allotransplantation with a short-course or low-dose
immunosuppression. Type 1 diabetics who have already
received a renal transplant would be candidates because
they are already obligated to chronic immunosuppression.
(2) Development of improved biocompatible encapsulation
materials and capsule designs.
(3) Define new approaches to gain oxygen delivery to encap-
sulated islets to improve both early engraftment and long-
term survival.
(4) Define optimal transplant sites that have adequate capacity/
surface area and that circumvent the differences of the
intraportal and intraperitoneal sites.
APAND INSULIN DELIVERY SYSTEMS
Current State of the Field
New treatments for T1Dmay be suited to different clinical
situations and stages of disease—it is unlikely that 1 form of
treatmentwill be best for all patients in the foreseeable future.
Diabetes evolves over years from diagnosis when significant
endogenous insulin secretion still exists to established
disease with barely any endogenous insulin (C-peptide
negative). This progression is associated with increasing
lability and difficulty in achieving glycemic control and
increasing prevalence of hypoglycemia unawareness. Hy-
poglycemia unawareness in most cases results from physio-
logical adjustment to recurrent hypoglycemia with reduced
counter-regulatory hormone production and reduced auto-
nomic symptom response. It does not result from structural
autonomic neuropathy. The frequency of severe hypoglycemic
episodes is strongly correlated with unawareness. This is a
major clinical challenge in people with established diabetes
and has become the usual indication for pancreas or
islet transplantation alone (in the absence of a kidney trans-
plant). Overnight hypoglycemia is also a significant problem
and is the major cause of the “dead-in-bed” syndrome.
One possible treatment—the AP—can be traced back
decades to studies demonstrating the possibility of external
blood glucose (BG) regulation using intravenous BG mea-
surement and infusion of insulin and glucose.172,173 With
the establishment of subcutaneous insulin delivery174,175
and minimally invasive continuous glucose monitoring
(CGM)176 as viable diabetes technologies, increasing aca-
demic and industrial effort was focused on the develop-
ment of closed-loop systems using CGM coupled with a
subcutaneous insulin pump. In 2004, the Advanced Insulin
Infusion using a Control Loop project based in Cambridge
reported the first promising results177; in 2006, the JDRF
Artificial Pancreas Project was initiated; in 2008, the US
National Institutes of Health launched an AP initiative;
and in 2010, the European AP@Home consortium was es-
tablished. A roadmap toward a viable AP was accepted,
which included sequential steps beginning with automated
mitigation of hypoglycemia and progressing through control-
to-range and control-to-target toward fully automated,
possibly multihormonal, AP.178 By 2010, the AP became
a global research topic engaging physicians and engineers
in an unprecedented collaboration. Key milestones of this
development are described in recent reviews.179-182
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In those with early T1D (with preserved insulin secretion;
C-peptide positive), it is possible that the combination of re-
sidual β cell function and closed loop insulin delivery might
be safe and deliver very tight metabolic control. This may
have both short- and long-term benefits. In established diabe-
tes, closed loop systems may reduce or prevent overnight hy-
poglycemia. It remains to be tested whether in longstanding
diabetes closed loop delivery can restore hypoglycemia aware-
ness to the same extent that can be achieved by pancreas or
islet transplantation. It is also possible that if used widely
and early enough, the reduction in major hypoglycemia,
especially prolonged nocturnal hypoglycemia that occurs
frequently with conventional treatment, may be enough
to reduce over time the number of people suffering from
problematic hypoglycemia unawareness.
Current technology has shown that AP is able to im-
prove average glycemic control and simultaneously reduce
moderate hypoglycemia; thus, it is likely but untested that
the AP would be able to prevent severe hypoglycemia
known to cause seizures or loss of consciousness. Ongoing
AP trials aim to reduce mild hypoglycemia enough to allow
consistent restoration of hypoglycemia awareness similarly
to current studies of islet transplantation designed to include
patients with hypoglycemia unawareness experiencing fre-
quent disruptive severe hypoglycemic events. There are still
technological problems, such as accuracy of the glucose
sensor, network connectivity between the devices compris-
ing the AP system, and reliability of the insulin pump. Most
of these problems are currently being mitigated by algorithm
development, and technology improvements that are likely
to bring the AP to mainstream use in the not too distant fu-
ture.181,182 The table below summarizes certain advantages
of, and challenges to, AP systems:
Subcutaneous and implantable insulin pumps (CSII,
CIPII)—Continuous subcutaneous insulin infusion (CSII)
relies on providing basal and bolus insulin using insulin
analogs.189 Structured education programs teach patients
to adjust insulin doses based on premeal BG levels and car-
bohydrate intake and can achieve target glucose control
with lower rates of hypoglycemia. Forty percent of the
patients referred to the UK Dose Adjustment for Normal
Eating program have impaired awareness of hypoglycemia,
which is restored in 40% of those 1 year after UK Dose Ad-
justment for Normal Eating.190 Meta-analysis shows that
insulin pump therapy can provide a 4-fold reduction in the
rate of severe hypoglycemia events.191 Continuous intraperi-
toneal insulin infusion (CIPII) with an implantable pump is
available in a few countries. In a randomized, cross-over
study with CSII in a group of patients with a baseline HbA1c
approximately 8.2%, the use of CIPII was associated with
less severe hypoglycemia, although baseline rates were low,
with no difference in improvement of HbA1c approximately
0.5%.192 In a second study of similar design in a group of pa-
tients with a baselineHbA1c approximately 8.6%,CIPII was
associated with a 0.76% reduction in HbA1c compared with
CSII with no difference in time spent in the hypoglycemia
range or rate of hypoglycemia events.193 However, the need
for operative placement and reoperation on average every
few years to address complications, such as battery re-
placement, catheter occlusion, pump dysfunction, pain,
and infection, have limited broader CIPII application.194
CGM is available in some countries. Since the advent of
CGM technology,195-197 significant progress has been made
toward versatile and reliable CGM devices that not only
monitor BG day and night but also provide feedback to the
patient, such as alarms when BG reaches preset low or high
levels. A number of studies have documented the benefits
of CGM176,198-201 and charted guidelines for its clinical
use202,203 and its future as a precursor to closed-loop con-
trol.204,205 Although many studies have excluded patients
with problematic hypoglycemia, the largest trial of CGM
use to date showed a 0.5% improvement in HbA1c from
a baseline of 7% or greater with no increase in hypoglyce-
mia for patients 25 years or older who most often used
their glucose sensor during at least 6 or 7 days each week.
Another study demonstrated that CGM in children and
adults with a HbA1c less than 7.5% was associated with
a 0.27% improvement in HbA1c and less time in hypogly-
cemia.201 In a retrospective clinic-based analysis, use of
CGM in a cohort of patients with problematic hypoglyce-
mia at baseline was associated with a reduction in severe
hypoglycemia episodes from 8 to 1 per year, an improve-
ment in HbA1c from 8.1% to 7.6%, but no change in hy-
poglycemia awareness.206
Low glucose suspend (LGS) is considered a precursor
to closed-loop because of the information exchange be-
tween CGM and the insulin pump. Two randomized con-
trol trials, which were enriched to different levels with
ADVANTAGES KEY CHALLENGES
Potential cumulative effect of improved control; in particular improved average
glycemia, increased time in range, and reduced time in hypoglycemia
down to a minimum.
Subcutaneous delay and variability of insulin absorption and insulin action,183,184
CGM inaccuracy, noise, and loss of sensor signal.185,186
Can be available on consumer electronics (eg, smartphone); durable and
potentially upgradeable.
Patient-friendly user interface187; AP network quality and connectivity.181
Close to clinical reality. Cost—consumables approximately US $4000/y. Still will require some human
intervention.
Reduced demand on patient for close monitoring of glucose values and
computing of insulin doses, particularly overnight.
Loss of insulin infusion [cannula failure] and fault detection188; automated
handling of meals and exercise179; will still have alarms requiring human
intervention.
No immunosuppression. Insulin is still infused subcutaneously, ie, the wrong place, resulting in inferior
insulin action for the foreseeable future. Multiple devices and sites may be
difficult for some.
Can manage overnight [basal control] safely. Ability to cope with meals, exercise and illness needs to be tested.
Fault detection needs to be robust.
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hypoglycemia, showed significant reductions in hypogly-
cemia: automation to simulate pancreatic insulin response
showed a 38% reduction in nocturnal hypoglycemia com-
pared to CGM alone without increasing HbA1c.207 In the
second randomized control trial, LGS versus CSII showed
a significant reduction in severe hypoglycemia in patients
with impaired awareness of hypoglycemia that was associ-
ated with less time spent in the hypoglycemia range, and
again no change in HbA1c; however, the number of severe
hypoglycemia events was rather low at baseline and the pa-
tients are rather young with short disease duration.208
Closed Loop Control:
Algorithms
The central part of anyAP system is a control algorithm re-
ceiving CGM and CSII information and computing insulin
microdoses which are sent for delivery to the insulin pump
at short time intervals, typically every 5 to 15minutes. Various
types of control algorithms were introduced ranging from rel-
atively straightforward proportional-integral-derivative con-
trollers209 to complex model-predictive algorithms,184 and
empirical logic approaches.210 Essential for the design of a
closed-loop algorithm is a modular structure that defines the
control action211:
(1) Safety and prevention of hypoglycemia ranging from
straightforward LGS to sophisticated model-based hypo-
glycemia safety systems212;
(2) Control-to-range (known also as treat-to-range) which
mitigates both hypoglycemia and hyperglycemia and aims
the maintenance of BG levels within a certain range (eg,
4-10 mmol/l)213;
(3) Control-to-target which aims near-normalization of glyce-
mic control mimicking the pancreas action in health,
which always tends to bring glucose homeostasis to a set
point (eg, 5-6 mmol/L).
AP Technology
Forty years ago, the AP was a refrigerator-size device (eg,
the Biostator172). The first inpatient closed-loop control stud-
ies that began 8 years ago used AP systems based on laptop
computers wired to CGM and insulin pump.209,214-217More
recent studies took laptop-based systems to the bedside of
patients in overnight summer camp218 and home trials.219
However, such systems were unsuited for everyday free-
living use, and a different design approach was needed to
bring the AP truly home.220 In 2011, the first portable AP sys-
tem was developed at the University of Virginia using an An-
droid smartphone as a computational platform and was
tested in 2 pilot trials of outpatient AP done simultaneously
in Padova, Italy andMontpellier, France.221 These first studies
demonstrated that inexpensive consumer electronics devices
are capable of running closed-loop control, and therefore
smartphone-based systems may be 1 possible approach to
an affordable AP in the near future.181,182 The system can
be used as individual modules as well as a fully integrated
device. For example, the system can operate in a sensor-
only mode providing extension of the CGM receiver func-
tionality, predictive alarmsandcapabilities for remotemon-
itoring of the patient over the internet; or the system can
work as a pump “companion” providing wireless capabili-
ties and basal/bolus advice to the patient.
Clinical Trials
Extensive inpatient clinical studies were conducted in 2008
to 2012 using increasingly more sophisticated approaches:
manual adjustment of insulin delivery according to control
algorithm recommendations,214,215 overnight-only control,216
automated day-and-night closed-loop,217 dual-hormone con-
trolusingglucagonasanadditional controlmechanism,222per-
sonalized control algorithms,223 and monitoring of additional
input signals to the control algorithm (eg, heart rate) during
exercise.224 These studies demonstrated the superiority of
closed-loop control over standard insulin pump therapy in
terms of improved average glycemia, improved time within
target range, and reduced hypoglycemia. Similar results were
achieved by different control algorithms as demonstrated by
a comparative study.225 As noted above, the transition of the
AP to ambulatory use began in 2011 and since then studies have
been conducted in controlled outpatient settings (eg, hotel, guest
house),226,227 summer camps for childrenwith diabetes,218,228 and
patients' homes.229 Typically, studies that used laptop-based wired
systems were restricted to overnight bedside AP use,218,219,229
whereas studies using wireless portable systems were full-time,
day and night.226,227 In particular, the smartphone-based
systemmentioned above logged over 70 days and 200 nights
of closed-loop control so far.226-228 A number of clinical
protocols are under way with progressively longer duration
and relaxed setting transitioning to long-term AP trials at
home. Preliminary data were reported at the 2014 session of
Advanced Technologies and Treatment for Diabetes in Vienna
from studies at Cambridge, United Kingdom, and the Univer-
sity of Virginia, showing significant improvement of glucose
control overnight.
Pancreas transplantation represents the gold standard
β-cell replacement therapy. Islet transplantation is emerging
as aminimally invasive alternative to pancreas transplantation
that can provide near-normal glycemic control while ame-
liorating problematic hypoglycemia. As a benchmark, suc-
cessful pancreas transplantation fully normalizes glucose
homeostasis, normalizing HbA1c while abolishing hypoglyce-
mia, as evidenced by a CGM study in recipients of SPK trans-
plantation documenting amean glucose 5.6 ± 0.4mmol/L and
96% of time spent between 3.3 and 7.8 mmol/L not different
from 5.5 ± 0.4 mmol/L and 99% in a control group of healthy
volunteers. In a study of T1D patients selected for successful
SPK transplant (HbA1c ~5.2%), IAK (HbA1c ~5.5%) or
CIPII (HbA1c ~7.1%), glycemic control assessed by CGM
demonstrated mean glucose of 5.4 ± 1.1, 5.8 ± 0.8, and
7.8 ± 1.7 mg/dL, respectively, with significantly less glucose
variability in both transplant groups and no (SPK) to minimal
(IAK) time spent in the hypoglycemia range compared with
significantly greater number and duration of events with
CIPII.230 Another nonrandomized study compared patients
with a baseline HbA1c approximately 8.3% consecutively
treated with either islet transplantation or CIPII and followed
up or 3 years, and similarly demonstrated superior glycemic
control (HbA1c ~6.6 vs. 8.1% at 3 years) and reduction in hy-
poglycemia with the cellular replacement therapy; however,
adverse events occurred 4 times more often with islet cell com-
pared with CIPII therapy.231 In contrast, current use of AP
components, including insulin pumps, CGM, and LGS, can
improve, but not normalize, glycemia. Although it is tempting
to apply such technology to those experiencing problems with
hypoglycemia, information from this population is limited. In
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addition, inaccuracy of glucose sensors and variability in sub-
cutaneously delivered insulin absorption and action still limit
the application of AP technology. However, closed-loop con-
trol, albeit imperfect when compared to cellular replacement,
has the potential to become widespread by virtue of its acces-
sibility, plentiful supplies (as opposed to limited supply of is-
lets), ease of initiation without surgical intervention, and no
need for immunosuppression.
The Research Agenda
Metrics
The field of islet transplantation has developed quantita-
tive measures of glycemic lability and hypoglycemia severity
that ensure proper identification of those patients with
longstanding C-peptide–negative disease at greatest risk for
severe hypoglycemia231,232; these tools have been used to as-
sess CGM233 and should be further used to assess LGS and
the emerging components of the AP system. Sophisticated
analysis of glycemic control is possible with large amounts
of sensor data uploaded to the Cloud for remote analysis.232
Comparison of different technologies will be improved if the
samemetrics are applied to all, whereas at this stage, different
measures of glycemic control are used.
AP Technology
The transition of the AP to everyday diabetes therapy use
is contingent upon seamless concerted work of a device net-
work encompassing the patient. Achieving reliable system
operation is possible through 2 distinct routes:
(1) CGM-insulin pump communication and all control algo-
rithms are being implemented in the insulin pump. This
“traditional” approach is currently adopted by industry,
for example, Medtronic, Animas, and Roche. Advantages
include straightforward system integration and simulta-
neous testing of all system components. Disadvantages
are increased system cost, limited flexibility to use devices
interchangeably and select the best components from dif-
ferent manufacturers, slow life cycle of the technology
(typically 4-5 years), and potentially slower adoption of
new control approaches.
(2) Use of consumer electronics whenever possible. Advan-
tages include:
• Contemporary smartphones are: readily available and inex-
pensive, computationally capable of running closed-loop con-
trol, wirelessly connectable to CGM and insulin pumps and
capable of broadband communication with a central location
for remote monitoring and safety supervision, and no current
insulin pump offers all of these capabilities.
• The technological life cycle of a smartphone is months, as
opposed to years for insulin pumps; thus use of consumer
electronics allows easier hardware updates and keeping up
with contemporary user-interface appearance and device
form factor.
• Psychological studies show that many patients (particularly
children and teenagers) are reluctant to use their insulin pump
in public, missing boluses and slipping into poor glycemic con-
trol when privacy is limited (eg, during school days). However,
no one is embarrassed to use a smartphone, and that may be a
key to better patient engagement and better glucose control.
• Disadvantages include difficulties with system integration and
regulatory approval.
Bioartificial pancreas
A few years ago, we speculated that it would become pos-
sible to combine cellular and mechanical insulin replacement
in a single unified treatment strategy.234 Specifically, limited-
volume islet infusion can be used to initiate, but not complete
the process of β-cell replacement, partially mitigating hyper-
glycemia and restoring the counter-regulatory responses to
hypoglycemia. Additional insulin can be then delivered by a
closed-loop controller. Such a combination therapy could al-
leviate the problem of limited islet supply and at the same
time facilitate the work of the mechanical AP by aiding the
control algorithm with partially biologically restored glucose
control. Although such combination therapies have not been
attempted, primarily because the AP is still not ready for
long-term use, randomized controlled clinical trials could be
planned to compare cellular versus artificial insulin replace-
ment therapies, as well as combination “bioartificial” ap-
proaches in terms of effectiveness, cost, and availability of
the treatment. It could be hypothesized that: (i) limited islet
transplantation and/or regeneration would partially restore
β-cell function resulting in reduced glucose variability; (ii) ar-
tificial closed-loop would then deliver additional insulin, fur-
ther reducing glucose variability; (iii) in turn, reduced glucose
variability would exert less stress on the transplanted β cells,
thereby increasing their longevity. However, the addition of
the costs and risks of 2 new technologies may reduce the fea-
sibility of this approach.
Whether a bioartificial pancreas is feasible or not, it em-
phasizes that AP and cell-based technologies for glycemic
control have the potential to be used together, not only
separately. Treatment for people with T1D should include
consideration of these new technologies as well as conven-
tional therapy. It is reasonable to consider testing AP in
patients early in the course of uncomplicated T1D when glu-
cose counter-regulatory defenses remain intact, thus mini-
mizing the risk for severe hypoglycemia. For patients with
established (C-peptide negative) T1D experiencing frequent
severe hypoglycemia despite best medical management, islet
transplantation appears the most promising alternative to a
whole pancreas transplant.
Summary of Research Priorities
(1) Assessment of state of the art AP technology with stan-
dardized measures of glycemic lability and hypoglycemic
severity developed by the islet transplant field.
(2) Full incorporation of consumer electronics (smartphone
technology) to allow remote monitoring/supervision,
opportunity for frequent hardware and software up-
dates, and to negate the psychological stigma of in pub-
lic pump use.
(3) Consider assessment of combine AP-islet transplant ther-
apy to address the limited islet supply and need for multi-
ple islet doses and perhaps limit β cell stress, thereby
improving islet performance and longevity.
IMMUNE TOLERANCE FOR ISLETAUTOIMMUNITY
AND ALLOIMMUNITY
Current State of the Field
There are no currently widely available, safe, and exten-
sively validated approaches for establishing tolerance for islet
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transplantation in humans. Although a large number of ap-
proaches seem to be efficacious in rodent models, most have
failed to translate into success in primate or porcine large an-
imal models. Some success has been achieved in humans in
renal transplant protocols which require low-risk donors
and recipients, extensive immunosuppression, and compo-
nents of hematopoietic chimerism. Moving forward, there
are several principles to be taken into account. First, when
assessing tolerance for islets and because of the unique char-
acteristics of different immune responses (eg, memory, cross
reactivity, number of reactive clones, and cells), it is very
important to separately measure and assess responses to
autoantigens and to alloantigens. Depending on future po-
tential, responses to xenoantigens will also have to be sepa-
rately addressed. Second, it is important to have measures
not only of islet function and injury but also measures of im-
mune reactivity and immune regulation to prospectively
monitor recipients. Third, it is clear frommurine studies that
there are many components to immunity, and that tolerance
is achieved only by targeting the distinct arms of the immune
response. Broadly speaking, innate B-cell andT-cell responses
must be controlled to induce andmaintain tolerance. It is also
clear that tolerance is achieved not only by preventing these
distinct responses but also by generating regulatory phenom-
ena. Fourth, it is clear from murine studies that the most ro-
bust tolerance for both autoimmunity and alloimmunity is
achieved in protocols that incorporate some form of hema-
topoietic stem cell chimerism along with immune regula-
tion.235,236 Chimerism successfully prevents the B- and T-cell
components of adaptive immunity while simultaneously gen-
erating a variety of suppressor and regulatory mechanisms
(eg, anergy, deletion, suppressor cells).237
Current clinical studies define various approaches that
hold some promise for tolerance induction or provide a guide
for approaches that do not work (Tables 2 and 3). The
ONE Study (www.onestudy.org) is currently validating
procedures for generating suppressive, Treg and mesenchy-
mal stem cells that can be grown and manipulated. Although
there is currently no information yet as to efficacy of these
regulatory cells in transplantation, safety studies have been
performed in patients with T1D. Low dose IL-2 has been
shown in human clinical trials to increase peripheral Treg cell
and ameliorate autoimmune HCV-induced vasculitis.238,239
Current T1D clinical prevention and intervention trials
may define lead assays, drugs, and procedures for overcom-
ing autoimmunity at early or late stages (Tables 2 and 3). A
number of observations, failed trials, and/or validation stud-
ies have yielded important and surprising results that provide
extremely important guidelines for translation of informa-
tion to tolerance trials and for interpreting putatively interest-
ing signals in the preclinical literature.
Grant et al240 reported on the results of an independent
laboratory's tests of novel agents to prevent or reverse T1D
in the nonobese diabetic mouse, diabetes prone BB rat, and
multiple autoimmune disease–prone rat models. Methods
were developed to mimic human clinical trials, including
prescreening, randomization, blinding, and improved glyce-
mic care of the animals. Agents were selected by an NIDDK
appointed independent reviewpanel. Agents selected to prevent
diabetes at later stages of progressionwere: a STAT4 antagonist
(DT22669), α 1 anti-trypsin, celastrol, and a macrophage in-
flammatory factor inhibitor (ISO-092). Agents tested for
reversal of established T1D were: α 1 anti-trypsin, tolero-
genic peptides (Tregitopes), and a long-acting formulation
of GLP-1 (PGC-GLP-1). None of these agents prevented or
reversed T1D, whereas the positive control interventions
were effective: anti-CD3 reversed diabetes in the NOD
mouse, dexamethasone prevented diabetes induction in the
multiple autoimmune disease–prone rat, and cyclosporine
prevented diabetes in the BBDP rat. This important study
highlights the limitations of much of the primary rodent liter-
ature and strongly demonstrates that stringent confirmatory
testing will be required in rodent models before translation
to large animal or human experimentation.
Sarikonda et al241 reported that combination therapy with
anti-CD20 and either oral insulin or proinsulin does not pro-
tect hyperglycemic NOD mice, but the combination with
proinsulin offers limited efficacy in T1D prevention. The
ITN, TrialNet, andNHP studies listed in Tables 2 and 3 dem-
onstrate many outright failures or very limited signals for
OKT3 (anti-CD3ɛ), thymoglobulin (polyclonal antithymocyte
globulin), α 1 antitrypsin, oral insulin, rituximab (anti-CD20),
daclizumab (anti-IL-2Rα), abatacept (CTLA4-Ig), alefacept
(LFA3-Ig), and canakinumab (anti-IL-1β). Although these re-
sults are obviously disappointing, they also show what does
not work so that nonproductive avenues of research are no
longer pursued.
The current state of the art does not define how best to
plan the sequence of preclinical or clinical trials for interven-
tions and markers. For example, should NOD or humanized
mice be used to evaluated treatments for the autoimmune
component? What is the best model to provide supporting
data before initiating clinical trials? Should we first validate
biomarkers and then go to clinical trials, versus validate an
approach that achieves tolerance in primates first? If clinical
trials are contemplated, who is best suited to which therapy?
How is safety defined in clinical tolerance trials, especially for
treatment of autoimmunity and alloimmunity in T1D, where
alternative treatments (ie, semisynthetic insulins, closed loop
insulin pumps) are rapidly improving? Should trials first be
performed in transplant populations with larger numbers of
patients (ie, renal allografting)?
It is important to realize that immunologic interventions
can likely be enhanced by other nonimmunologic approaches
in islet transplantation. Thus, there are multiple opportuni-
ties for cross-fertilization with technologies and approaches
from the other workgroups. Encapsulation techniques may
obviate the need either to measure immunity or to develop
novel immune or tolerance techniques. It is conceivable that
a perfect encapsulation systemwill allow long-term graft sur-
vival with conventional immunosuppression accompanied
by immunosuppression minimization and weaning. Although
xenografts present a large series of novel antigens towhich it is
currently very difficult to provide adequate immunosuppres-
sion, encapsulationmay overcome these problems bymasking
antigens and/or protecting from effector mechanisms of in-
flammation and rejection. The β-cell regeneration and stem
cell technologies may overcome some toxic effects of con-
ventional or novel immunosuppression. Likewise, enlarging
and continually replacing the β cell mass may also overcome
immune reactivity and help to generate exhaustion in antigen-
reactive clones of T cells and B cells. Conceivably, the com-
bination of encapsulation, regeneration, stem cells, and
xenotransplant along with conventional immunosuppression
S24 Transplantation ■ February 2016 ■ Volume 100 ■ Number 2S www.transplantjournal.com
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and monitoring may achieve the goal of long-term islet func-
tion with ease of monitoring plus minimal toxicity.
Obstacles to Application of This Therapy
There are many unsolved immune barriers imposed by the
lack of markers for diagnosing recurrence, rejection, toler-
ance; infections which stimulate innate immunity and tissue
inflammation; cross-reactive or antigen-specific memory T
cells andmemory B cells for which there is no effective immu-
nosuppression; and hematopoietic stem cell engraftment
without graft vs host disease using nontoxic conditioning.
Overcoming these barriers will require effective and vali-
dated biomarkers for immune monitoring, effective anti-
inflammatory immunosuppression which targets innate and
adaptive immunity without toxicity, effective immunosup-
pression for memory responses, and far more reliable and
less toxic procedures for achieving bone marrow chimerism.
There are many unsolved nonimmunologic barriers which
include limitations to islet mass and quality; lack of specific,
sensitive, and reliable islet imaging or functional monitoring;
and islet toxicity imposed by many immunosuppressive and
immunomodulatory drugs and procedures. Overcoming these
barriers will require progress in islet isolation, regeneration
and stem cells; validated measures and markers of islet mass
and function; and novel immunosuppressive regimens that ob-
viate the need for islet toxic agents.
The Research Agenda
There are several approaches which could achieve matu-
rity within the next few years and be ready for large scale
clinical trials. As noted above, hematopoietic stem cell chi-
merism is validated for proof of concept in rodent, large
animal, and human studies. Additional approaches to en-
hance this modality may include vascularized bone mar-
row and/or intrabone marrow injection of hematopoietic
stem cells to improve the establishment and durability of chi-
merism. Rodent studies242 achieving durable chimerism by
adding expanded recipient Treg cells and human studies safely
achieving transient chimerism243,244 provide proof of concept
that the combination of Treg cells plus nonmyeloablative bone
marrow transplantation has great potential to achieve durable
and safe chimerism.
The T1D early-onset and preventive studies outlined
above may soon point the way to therapies that are easily
adapted to islet transplantation. We can expect results over
the next few years, although there are no currently validated
therapies or prime candidates.
Biomarkers are critically required to move the field for-
ward. A technology that will dramatically advance the field
is a validated assay or biomarker that effectively yields highly
predictive data for immunosuppression and tolerance on the
one hand, and antigen reactivity on the other hand. Assays
based on T cell ELISpot, serum DSA, circulating plasma
β-cell DNA, or peripheral blood mononuclear cell profiling by
FACS orRT-PCRhave been shown at times to be strongly asso-
ciated with important immune events and outcomes.245,246
There are interesting hints that B cells or NK cells are markers
or mechanistically related to tolerance. However, the associa-
tions are not so strong that that these tests are highly predictive
or actionable, and none of these tests or combinations of these
tests have areas under the curve greater than 0.95, which is
required for a reliable clinical test. Array platforms that
measure DNA simple nucleotide polymorphisms, messen-
ger RNA, microRNA, proteins, metabolites, or microbiota
TABLE 3.
TrialNet Studies
Title Enrollment Launch Completion
Effects of oral insulin in relatives of individuals with T1D in the
diabetes prevention trial—type 1
Target: 372 1994 2003
Final: 372
“Pathway to prevention” natural history study of the development
of T1D (screening, follow-up of at-risk)
Ongoing 2004 Ongoing
Screening: 114 879
At risk: 3334
New-onset T1D—Mycophenolate Mofetil/Daclizumab Clinical Trial Target: 120 2004 Enrollment: 2007
Final: 126 Outcome: 2009
Effects of rituximab on the progression of T1D in new-onset subjects Target: 66 2006 Enrollment: 2007
Final: 87 Outcome: 2008
Oral insulin for prevention of diabetes in relatives at risk for T1D Target: N/A* 2007 Enrollment: 2015
(Testing prediction from DPT-1 Oral Trial) To date: 240 (1° stratum) 350 (all strata) Outcome: 2017
Nutritional intervention to prevent T1D—pilot trial Target: 90 2006 Enrollment: 2008
To date: 123 Outcome: 2009
Effects of CTLA-4 Ig (abatacept) on the progression of T1D
in new onset subjects
Target: 108 2008 Enrollment: 2009
Final: 112 Outcome: 2011
Effects of CTLA-4 Ig (Abatacept) for Prevention of Glucose tolerance in
relatives at risk for T1D
Target: 206 2013 Enrollment: 2017
To date: 4 Outcome: 2019
Effects of canakinumab on the progression of T1D in new onset subjects Target: 66 2010 Enrollment: 2011
Final: 71 Outcome: 2012
Anti-CD3 (teplizumab) for prevention of diabetes in relatives at risk for T1D Target: N/A* 2011 Enrollment: 2016
To date: 26 Outcome: 2018
Long-Term Investigative Follow-Up Trial (LIFT) Target: TBD 2012 Ongoing
Trichuris Suis Ova (TSO) to prevent epitope spreading in people at risk for T1D Target: TBD 2013 TBD
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are all available and have all been proposed as possible hy-
pothesis generating approaches in small clinical studies.
None are validated in clinical transplantation. For autoim-
munity, biomarkers may have to be validated in the T1D
studies and extended to islets. For alloimmunity, bio-
markers may have to be validated in larger studies in bone
marrow transplant and kidney or liver transplants before
attempting to translate to islets.
Specific targeting of Tand Bmemory cells to prevent recur-
rent autoimmune disease and chronic ongoing rejection is re-
quired. No current agents have been shown to be clinical
efficacious in this regard. Although Alefacept did have some
effects on memory by peripheral lymphocyte subset analysis,
it was unable to have a clinical impact on memory responses
in kidney clinical trials and it is clear that all other currently
approved drugs are not effective in safely controllingmemory
responses. Success and validation may first have to come
from bone marrow transplant, kidney, or liver transplants
and then translated to islets.
Encapsulation technologies and novel sites of transplanta-
tion may mitigate issues related to islet quality, islet quantity,
islet regeneration, tolerance, innate immunity, and memory
responses. The experimental approaches to site and to encap-
sulation are relatively advanced and may provide the ability
to move forward rapidly.
It is clear that a combination of several approaches out-
lined abovemust be considered.247 Combinatorial approaches
will undoubtedly create significant contractual, regulatory,
and safety hurdles.
What Is the Potential for the Treatment of Diabetes
It is noteworthy that minimal or minimized immunosup-
pression is widely used and potentially ready to implement
in islet transplantation. A regimen consisting of transient
steroids, transient anti-inflammatory (eg, TNF-α blocker),
CNI-free, mTORi-free or transient, and costimulatory block-
ade (Belatacept) has some proof of concept. An S1P1modula-
tor (Fingolimod) could be added to this regimen. A major
barrier to implementing this approach is lack of validated bio-
markers for islet function and immune monitoring. Addition-
ally, it may be argued that any protocol relying on long-term
immunosuppression, even at low levels, could only be applied
in patients with life-threatening complications of diabetes,
such as hypoglycemic unawareness. Given the excellent stan-
dard of care for diabetes that is currently available without
transplantation, the application of transplantation to broader
diabetic populations will only be ethically feasible when ap-
proaches that do not require long-term immunosuppression,
such as tolerance or encapsulation, are successful and safe.
The Treg cell therapy will likely be part of a combination
therapy approach. In particular, mixed chimerism induced
and sustained by Treg cells plus nonmyeloablative condi-
tioning may be one of the most likely approaches to be tried
in islet transplantation. As progress is made in Treg cell
therapy and nonmyeloablative conditioning in other areas
(eg, autoimmunity, cancer), those results may be translated
to islets.
If substantial progress is made in stem cells, encapsulation,
β-cell regeneration, isolation, imaging, biomarkers, or xeno-
transplantation, each of these areas will synergize for the in-
duction and maintenance of tolerance.
Summary of Research Priorities
(1) The recent success of chimeric tolerance in renal transplan-
tation potentially sets the stage for application to islets.
The use of protocols with high-level donor chimerism
may simultaneously achieve allotolerance and rid the host
of their native autoimmune prone T-cell repertoire.
(2) Costimulation blockade with simultaneous targeting of
CD28-B7 and CD40-CD40L remains a scientifically at-
tractive approach. New CD40 targeting agents in con-
junction with the recently approved anti-B7 belatacept
may permit such testing in the near future.
(3) Trials of innovative regulatory cell based approaches (Treg
cells) are also attractive in that it may be possible to interrupt
in parallel auto and alloimmunity with precise antigen
specificity.
STEM CELLS AS A SOURCE FOR b CELLS
Current State of the Field
Diabetes is a debilitating disease characterized by a chronic
inability to normalize BG levels. Transplanting cadaveric
pancreata or isolated pancreatic islets can restore glucose
homeostasis, but organ demand outstrips supply and donor
quality contributes to short-term complications. Consequently,
there is significant interest in alternative sources of IPCs. To
overcome the limitations of currently available therapies, re-
search efforts have focused intensively on generating func-
tional β cells or endocrine cell clusters from stem cells. A
variety of stem cell types have been considered as potential
future sources of transplantable β cells which include human
pluripotent stem cells (hPSCs), such as hESCs and human-
induced pluripotent stem cells (hiPSCs), mesenchymal stem
cells generally isolated from bone marrow or cord blood,
stem cells isolated from adult tissues, or directly reprog-
rammed somatic cells. This review will focus on pluripotent
stem cell (PSC) and reprogrammed somatic cell sources. Al-
though the concept of reprogramming somatic cells directly
into β-like cells is in its infancy, recent exciting progress in
the PSC field has led to refined protocols yielding highly
enriched populations of monohormonal insulin-secreting cells
and the initiation of pilot clinical trials.
Pluripotent Stem Cells
The PSCs are characterized by 2 features: their ability to
differentiate to any of 3 somatic cell lineages (ectoderm, en-
doderm, or mesoderm), and their ability to replicate indefi-
nitely in a stable pluripotent state.248-250 Because PSCs can
evade senescence in culture, they provide an unlimited supply
of cells suitable to meet the demand for a replacement cell
therapy.249 The PSCs can be directed to differentiate to a va-
riety of specific lineages with relatively high efficiency.251,252
The hESCs were first isolated and cultured by Thomson using
inherently variable mouse fibroblast feeder cells and serum
supplemented media.253 Significant improvements now allow
derivations and stable extended culture under defined xeno-
free conditions yielding cells with a normal genetic karyotype
suitable for cell banking and clinical applications.254-256
A second pluripotent cell source originates from somatic
cells which can be reprogrammed to a pluripotent state through
a process first identified by Shinya Yamanaka and Sir John
Gurdon.257-259 Reprogramming can be accomplished by
forced expression of a combination of transcription factors
(eg, OCT4, SOX2, KLF4, and cMYC or OCT4, SOX2,
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NANOG, and LIN28), a process initially reported using
retroviral transfection techniques.258,259 Subsequent stud-
ies showed that reprogramming could be achieved using
nonintegrating episomal vectors based on Epstein-Barr virus
or Sendai virus delivery systems260-263 and, more recently,
with RNA- or protein-based methods.264,265 Many human
cell types have now been reprogrammed to iPSCs, for exam-
ple, adult and embryonic fibroblasts, mononuclear peripheral
blood cells, T cells, islet cells, pancreatic acinar cells, and hair
follicle cells, among others. Human iPSCs have been derived
from patients with a variety of different diseases including di-
abetes.266-268
Direct Reprogramming
Rather than generating stem cells from somatic cells and
subsequently differentiating them to the desired lineage, at-
tempts have beenmade to circumvent this process and induce
direct reprogramming of somatic cells toβ cells, either in vivo
or in vitro. In this method, enforced activation of key pancre-
atic transcription factors, usually in combinations, is used to
drastically alter the program of expressed genes thereby lead-
ing to a dramatic change in phenotype, often across typical
lineage boundaries.269 Such an approach has been at-
tempted in several different cell types, such as pancreatic acinar
cells,270-272 hepatocytes,273 and fibroblasts.274 Although so-
matic cell reprogramming to pancreatic lineages involves epi-
genetic conversion, it is not known whether cells transform
directly into β cells, or whether they first revert to a multi-
potent state and then redifferentiate toward β cells (ie, 2-step
process) or whether certain cell types are more efficiently
reprogrammed. Also, whether such conversions result in stable,
robustly functional β cells remains to be determined.
Conversion of hPSCs to β Cells
The overall preclinical research goal of the field is to
achieve efficient derivation of a functionalβ cell mass in vitro
that is able to rapidly and reliably cure diabetes in mice, both
longstanding gold standard preclinical diabetes assays. To
achieve in vitro conversion of hPSCs to β cells, a highly pro-
ductive approach has proven to be the application of knowl-
edge gleaned from developmental biology studies. However,
most information about pancreas development has been ob-
tained from organisms, such as frogs, chickens, zebrafish,
andmice, and it is well known that aspects of pancreas devel-
opment and islet biology differ between humans and lower
organisms.275-277 Because of this, refinement of differentia-
tion protocols has progressed through a combination of
strategies that include both rational design and empiric test-
ing of developmentally important effector molecules and
monitoring expression of key transcription factors. These en-
deavors have also been complemented by an increasing un-
derstanding of the epigenetic landscape and transcriptional
profile of human pancreas development and fully differenti-
ated β cells.
In vivo pancreatic development is a complex process in-
volving sequential lineage restriction steps to form a compos-
ite, well-vascularized endodermally derived organ consisting
of acinar, ductal, and endocrine tissues.278-280 Based on prin-
ciples of vertebrate development, a multistep model of β-cell
formation from stem cells in vitro has been proposed,281
attempting to recapitulate sequential stages of in vivo
development including gastrulation, endoderm specifica-
tion, gut-tube morphogenesis and organ budding from
the gut tube, and finally organ-specific cellular differentia-
tion within the organ bud. This multistep model has since
provided a foundation for methods and protocols applica-
ble to pluripotent stem cell differentiation. A full descrip-
tion of pancreas development and the evolution of β cell
in vitro differentiation protocols over the last decade is be-
yond the scope of this review, and the reader is referred to
the following references: Hosoya et al, Alexander and
Stainier, Clements et al, and Shen.282-285
Rapid progress is being made to improve and refine in
vitro differentiation protocols to achieve monohormonal
β-like cells that express key maturity markers and exhibit ro-
bust glucose-stimulated insulin secretory responses. Many
believe that a more mature differentiated cell will be more ad-
vantageous therapeutically as well as provide a tool to facili-
tate studying β-cell pathophysiology and testing of novel
pharmaceuticals. Until recently, in vitro–derived IPCs largely
exhibited a polyhormonal phenotype282,283,286-289 and most
likely corresponded to cells of the primary endocrine transi-
tion observed in murine and human development,290,291
which ultimately do not give rise to adult β cells. Instead,
adult β cells are thought to arise from a distinct developmen-
tal event, the secondary transition, marked by transient
expression of neurogenin-3 (Ngn-3). Although the precise
reasons for incomplete differentiation under some conditions
are still unclear, it is worth noting that immature phenotypes
are also observed when other lineages, such as blood, car-
diac, and neural cells, are derived from PSCs. Polyhormonal
endocrine cells appear to have reduced levels of, or lack, im-
portant β-cell transcription factors, such as PDX1, NKX6.1,
andMAFA,286,287 and in some cases, key β-cell transcription
factors, such as PAX4 and ARX, are misexpressed compared
with adult human β cells in vivo.286,287 From a functional
viewpoint, immature hPSC-derived insulin-positive cells
appear to express reduced levels of other important genes in-
cluding potassium channels, proconvertases, Zinc trans-
porters, islet-associated polypeptide (IAPP), and urocortin3
relative to adult β cells.40 Thus, the expression of these markers
was essential for screening conditions that yielded more
mature functional β cells in vitro.292
Several groups have recently reported improved differenti-
ation protocols, which achieve monohormonal β cells and
better in vitro functionality, promising to finally remove this
longstanding roadblock.293-295 Interestingly, different proto-
cols were used by each of these groups yet there were some
commonalities. By extending the culture period, including
3-dimensional suspension culture and exposure to ALK5iII,
Shh inhibitors (SANT1 or KAAD cyclopamine), γ secretase
inhibitors to inhibit Notch signaling, and thyroid hormone
(T3), these three groups were able to enhance glucose-
stimulated insulin secretion (GSIS) in vitro. However, Rezania
et al292 showed that their cells exhibited dampened secretory
characteristics in perifusion assays compared with human
islets. Furthermore, although similar results in GSIS assays
were achieved with hPSC-derived β cells and human islets,
the degree of variability from preparation to preparation
of hPSC-derived β cells was surprisingly high.292,294 Impor-
tantly, the insulin-positive cells displayed a monohormonal
phenotype with improved expression of key β-cell signature
genes. Although there were many differences in the culture
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conditions among these recent reports, it is still not entirely
clear whether all of the components in each protocol are nec-
essary andwhether the makeup of the cell populations derived
by the different protocols is the same. Nevertheless, these cur-
rent reports demonstrate rapid progress in the field toward
achieving a more physiologically functional β-like cell in vitro
from hPSCs.
Critical progress in efficiently reversing diabetes in mice
was also reported this past year.292-294 Until recently, when
hPSC-derived pancreatic tissues were transplanted into im-
munodeficient mice, either under the kidney capsule or into
the epididymal fat pad or in an immunoisolation device in
the subcutaneous space, the graft did not regulate glucose
or produce secreted C-peptide immediately.296-384 Instead,
the graft appeared to mature over many6,13-20 weeks to form
functional pancreatic tissue in a time frame similar to the in
vivo maturation of human fetal pancreas.300 The mature
graft ultimately did contain islet-like structures comprised of
α (glucagon), β (insulin), δ (somatostatin), ghrelin, and pan-
creatic polypeptide hormone-producing cells and is compe-
tent to maintain glucose homeostasis in mice made diabetic
with alloxan or streptozotocin despite imperfect insulin secre-
tory kinetics of hPSC-derived endocrine grafts.301 Efficient in
vivo endocrine maturation appeared to be dependent on a
sufficient number of Nkx6.1 + PDX1+ pancreatic progenitor
cells (PPCs) in the transplanted population,298 and if/how the
cells were encapsulated.301 Although the delayed correction
of chemically induced diabetes by hPSC derivatives repre-
sented an important preclinical milestone, there remained
great interest in accelerating maturation in vivo. Indeed, 2
studies have now reported more rapid (2 weeks and 6 weeks)
reversal of murine diabetes after transplanting more mature
cells under the kidney capsule in Akita and streptozotocin
models, respectively.292,294
Now that the derivation of hPSC-β-like cells in vitro ex-
hibiting improved physiological and phenotypic characteris-
tics of adult, mature β cells resulting in more rapid cure of
diabetes in mice has been achieved, the next questions likely
to arise are: what accounts for the GSIS variability and damp-
ened insulin secretory kinetics in perifusion assays and can this
be improved?Will amacroencapsulation device provide a suit-
able environment for mature cells as it does for maturing pro-
genitors? Other questions concern the delivery of these cells to
patients: What cell population is the best to transplant? Are
progenitors sufficient to transplant or is a terminally differen-
tiated functional population better? Perhaps amixed or hybrid
population is a better choice? Is a mixture of endocrine cell
types necessary or beneficial and to what degree, or is it suffi-
cient to transplant a graft solely composed of β cells? Finally,
and perhaps ideally, can one derive/engineer a renewable, yet
fully differentiated β cell from stem cells? Many of these ques-
tions should be addressed in preclinical animal models.
Reports of pancreatic lineage differentiation and β-like cell
formation in vitro have come from many laboratories with
many different cell lines, using a variety of culture protocols.
However, few protocols have been compared head to head;
even fewer have directly compared multiple different cell lines
in parallel. Thus, which line and which protocol provides op-
timal pancreatic β cell differentiation have not been deter-
mined prospectively. Given genetic and epigenetic differences
of different PSC lines, it is not surprising that different cell
lines can behave dissimilarly under the same conditions.
Analyses of nonpancreatic cell types within differentiation
cultures, regardless of the protocol, have been limited. These
nonpancreatic cell types, including but not limited to undif-
ferentiated cells, could potentially inhibit or enhance ongoing
differentiation. The retention of undifferentiated cells through
later culture stages raises the specter of teratoma formation
after transplantation. Most culture protocols published to
date generate heterogeneous populations with some un-
wanted cells, which brings up several questions: how pure
does the population need to be? How precisely defined does
the cellular product need to be before it is deemed suitable
for therapeutic use? Are certain unwanted cell types accept-
able while others are not?
Regardless of whether transplantation of fully functional β
cells or PPCs is the therapeutic platform, both strategies would
benefit from technology that modifies the immunogenicity
of the graft, or induces host immunological tolerance, or pro-
tects the graft from host alloimmune and autoimmune re-
sponses. Ongoing efforts are addressing this need through
use of immunoisolation devices, modified stem cells,302 ad-
vanced immunosuppression protocols,303 tolerogenic strategies,
or using syngeneic hiPSCs. Macroencapsulation approaches
are particularly attractive because they have the benefit of
graft cell containment, reducing the risk of excessive growth
or the spread of cells with teratoma-forming potential as well
as limiting possible alloimmune and autoimmune damages.
Obstacles to Application
The achievement this past year of improved in vitro GSIS
andmore rapid reversal of diabetes in mice was amajor mile-
stone. Yet, many clinicians may still view the variable GSIS
results and subnormal insulin secretory kinetics in perifusion
assays that have been reported as a substantial obstacle to
widespread application of this technology.Why has this mile-
stone been so hard to achieve and how will we know when
we have achieved it? The field would benefit from a consen-
sus agreement as to what are benchmark phenotypic and
functional characteristics of an in vitro hPSC-derived β cell.
Most would agree that at the very minimum the following
should be achieved: (i) a consistent, reproducible stimulation
index without secretagogues of at least 2 to 3, and (ii) imme-
diate or near immediate reversal of diabetes in mice with a
normal glucose tolerance curve and stimulated C-peptide re-
lease in response to IVor PO glucose, which is eliminated if
the graft is removed. A more stringent definition might in-
clude results of a panel of phenotypic markers, GSIS includ-
ing secretagogues, estimation of proinsulin-insulin ratios,
and insulin secretion kinetics derived from perifusion assays
that mirror human islets. Additionally, determining physio-
logical responses at the single-cell level may be valuable,
given the possible heterogeneity of the insulin + cell popula-
tions. A comprehensive analysis of the resulting β-cell popu-
lation will benchmark the degree of functionality achieved
and facilitate comparisons between cells produced using dif-
ferent protocols. If not transplanting a functional β cell,
how long will patients be willing to wait before they are able
to eliminate insulin therapy—or how long will a transplant
be allowed to persist before it is deemed a failure? Moreover,
many clinical events could thwart in vivo maturation and the
development of functionality, such as rejection, recurrent au-
toimmunity, or toxic immunosuppressant medications.
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An important part of preclinical evaluation of a possible
therapy is to understand the immune responses to hESC/
iPSC-derived PPCs or β cells in immunocompetent hosts and
to devise ways to protect cells from alloimmunity and auto-
immunity. To date, these clinically relevant questions have
not been addressed in depth. Although encapsulation as a
transplant delivery systemmay demonstrate efficacy, it is also
possible that graft damage will still occur because many cur-
rent devices do not effectively exclude cytokines. More stud-
ies evaluating host alloimmune and autoimmune responses
to encapsulated hESC-derived β cells are needed. In an ideal
scenario, customized patient-specific iPSC lines may obviate
the need for immunosuppression. However, existing data
are unclear about whether syngeneic iPSC progeny would
be destroyed after transplantation304,305 and studies to date
do not address this question specifically for pancreatic line-
ages. Furthermore, it is currently unknown whether synge-
neic grafts derived from Type I diabetes mellitus patients
will indeed elicit immune responses or be susceptible to recur-
rence of autoimmunity. Thus, more work needs to be done to
clarify and better characterize the anticipated immune re-
sponses to syngeneic and allogeneic hPSC-PPC orβ cell grafts.
Moreover, based on the absence of autoimmunity in Type 2
diabetes mellitus patients, it may be reasonable to first test
syngeneic iPSC-derived β cell transplants in this population.
Teratoma formation, ormalignant transformation of a ter-
atoma into a teratocarcinoma, is a concern of any proposed
hPSC-based therapy. With teratomas reported in the context
of a number of current in vitro pancreatic differentiation
methods, effective, safe, simple, and inexpensive methods to
prevent or limit teratoma formation are needed. Further-
more, it will be necessary to quantify the risk for a given
cellular graft in order to assess its risk-versus-benefit ratio.
Therefore, developing a predictive, quantitative assay in
which to test a cell product would benefit the field. Such an
assay could be an in vivo assay, such as the injection into
the hind limb of an immunodeficient mouse similar to what
is currently used to determine pluripotency of cell lines. How-
ever, this method is neither quantitative nor rapid. A rapid,
relatively high throughput in vitro assay would represent a
more ideal method, if available. The PluriTest assay may
prove to be valuable for this purpose.306,307 Ultimately, a
fully terminally differentiated purified cell population may
have an extremely low teratoma risk profile, but determining
this preclinically for a given cell population would have merit.
Macroencapsulation may very well be the least expensive and
most effective “teratoma prevention” method currently avail-
able, but improved, less fibrogenic, more proangiogenic, and
cytokine-excluding encapsulation methods may be needed.
Other methods could require genetic manipulation of the cells
beforedifferentiationandtransplantation;however,suchmethods
may carry their own attendant risks.
Current differentiation protocols use large quantities of
expensive growth factors. Can these be replaced with less
expensive small molecules that signal through the same re-
ceptors and produce the same biological results? An example
of this is the use of LDN193189, a bone morphogenic pro-
tein antagonist instead of Noggin in recent studies.292,294
High-throughput screens for small molecules which can re-
place expensive growth factors may not only allow the differ-
entiation process to be less expensive but also more efficient.
Additional optimization will be needed to scale up the
differentiation protocols to generate large numbers of β
cells to meet the demands of millions of diabetes patients.
Finally, regulatory considerations will present significant
challenges in this area. The use of cadaveric islets in trans-
plantation is already regulated in the United States as a
manufactured cell product. Stem cell-derived β-cell products
will likely be regulated similarly by most regulatory agen-
cies. Additional use of encapsulation devices, scaffolds, other
supporting cells, angiogenic agents, or immune modulatory
factors will render the therapy as a combination product.
There will be complicated preclinical data packages for these
combination products depending on the perceived risks of
the individual components and their combinations. Geneti-
cally modified lines may be subject to additional regulatory
requirements. Academic researchers and industry stake-
holders will have to work closely with regulatory reviewers
to manage reasonable amounts of preclinical work to justify
clinical trials. In addition, to use a cell line clinically, it is crit-
ical that cell lines be generated under current Good Manu-
facturing Processes (cGMP). Durruthy-Durruthy et al308
recently published on a rapid and efficient conversion of
integration-free human iPSCs and suggested strategies to
convert to cGMP culture conditions. Currently, there are nu-
merous groups developing cGMP iPSC lines (Cellular Dy-
namics International, National Institutes of Health, Riken
Institute, Roslin Institute).
Direct Reprogramming of Somatic Cells to β Cells
Another strategy for generation of IPCs in vivo or in vitro
involves reprogramming adult cells directly to a pancreatic
cell lineage. A number of groups have demonstrated that β
cells may be generated from non–β cells through ectopic or
artificially induced gene expression of a single transcription
factor (Pdx1) alone or with other pancreatic genes. Ectopic
expression of PDX1 is sufficient to convert fetal α-cells to
β-cells in vivo and can promote functional insulin expression
inmouse liver.309,310 Combinatorial transfections of the tran-
scription factor genes Pdx1,MafA, andNgn3 can reprogram
murine pancreatic exocrine tissue or liver to form functional
β-cells in vivo, and the resulting cells appear competent to
rescue animals from hyperglycemia.270,311,312 Ectopic Pdx1
expression can also induce fate conversion in vitro, as dem-
onstrated in the case of cultured keratinocytes converted to
a pancreatic β-cell fate.313 These aggregate results suggest
that ectopic expression of Pdx1, alone or with other genes,
may provide an alternative means of generating functional
β-cells. Recently, Zhu et al274 reported on the direct repro-
gramming of murine fibroblasts to definitive endoderm by a
transient expression of pluripotency reprogramming factors
in conjunction with a unique combination of small molecules
and growth factors. They then followed a differentiation pro-
tocol to develop pancreatic progenitors that reversed diabetes
in a rodentmodel. On the other hand, human pancreatic duct
reprogramming may be improved by Ngn-3 overexpression,
inhibiting Delta-notch signaling and coexpressing Myt1.314
These data demonstrate how the plasticity of adult cells, in
particular those of related lineage, might be harnessed to pro-
duce β cell phenotypes.
Many challenges on the road to clinical application remain
as this strategy is relatively young. The reproducibility and
functionality of resulting cells still need to be rigorously
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tested. Can the efficiency of an in vivo reprogramming ap-
proach be increased to achieve a suitable β-cell mass for
replenishment of lost β cells in large animals or humans?
Moreover, the long-term safety of reprogrammed cells is
not known. An advantage of direct reprogramming is that
cells would be syngeneic to the prospective recipient; yet, a
potential disadvantage is that autoimmunity may limit the
emergence of new β cells in T1DM patients. Nonetheless,
recent data provide significant encouragement that a direct
reprogramming approach could 1 day generate new β-like
cells ex vivo, or in a patient.
The Research Agenda
Refined and improved differentiation protocols are needed
to achieve consistently efficient yields of β cells in vitro which
exhibit normal insulin secretion kinetics. A better under-
standing of the signaling molecules regulating the later stages
of endocrine cell specification, delamination from the epithe-
lium, formation of islet cell clusters, and achievement of func-
tional GSIS during in vivo development would greatly aid the
field in achieving the milestone of robust functionality in
vitro. The field would undoubtedly benefit from having a
central core laboratory for comparisons of cells generated
by different protocols. Putting different cell populations from
a variety of laboratories and companies through a variety of
functional assays such as static incubation assays, perifusion
assays, gene and protein expression assays, and mouse trans-
plant assays, and so on to directly compare cells would be a
valuable endeavor for the stem cell community.
Identifying and isolating derived β-like cells for investiga-
tion would benefit from availability of advanced reporter
lines. A human ESC Insulin-eGFP reporter line generated
byMicallef et al315 has been used in several studies to charac-
terize insulin-positive cell expression profiles and physiol-
ogy.316,317 However, most in vitro differentiation conditions
generate insulin + glucagon + polyhormonal cells. Thus, it
would be beneficial if additional reporters such as forGlucagon,
PDX1, or Nkx6.1 could be engineered into the same cell
lines. Cell lines such as these would aid in isolating various
cell populations for further characterization and transplanta-
tion. Additionally, engineering antibiotic resistance genes
into the insulin, PDX1, and other relevant gene loci could fa-
cilitate reducing the heterogeneity and improving the purity
of the resulting populations. Efficient genome editing methods
are now available to accomplish this; however, they remain
costly and labor intensive.318-320
The current assay for pluripotency and estimating tera-
toma risk is time consuming and expensive. An improved
predictive assay would support the field by providing a reli-
able, rapid, sensitive, and quantitative measure of teratoma
risk. Such an assay would benefit preclinical studies antici-
pating investigational new drug submission. Another “safety
net” approach might involve developing hPSC lines that con-
tain suicide genes tagged to pluripotency or progenitor gene
promoters which may be valuable for ensuring removal of
undifferentiated or partially differentiated cells thereby re-
ducing the risk of teratoma formation.
To date in preclinical studies, stem cell β-like derivatives
have primarily been functionally tested in mouse models of
chemically induced diabetes, as a proof of principle. Few
other models have been tested because of the paucity of these
diabetes models existing on a suitable immunodeficient
background. Therefore, having readily available additional
diabetes murine immunodeficient models would benefit the
field. Additionally, more robust humanized murine models
as well as large animal models would also be advantageous
to studying the immunogenicity and dosing strategies of the
stem cell-derived β-cell populations.
Human iPSCs provide a valuable tool for disease model-
ing268,321-325 and several hiPSC lines have been generated
from patients with T1D and T2D.266,267,326 From a scientific
and diseasemodeling point of view, it would be useful to have
hiPSC lines from a variety of types of diabetes including
monogenic diabetes to take advantage of these possible in
vitro disease models. Repositories could be established and
then these models would need to be characterized and vali-
dated. The combination of data from genomewide association
studies, genome editing and hPSC-derived β cells, provide a
powerful set of tools to study the genetics of various forms
of diabetes and mechanisms of pancreas development.
Safety is a potential issue for virally derived hiPSC lines
intended to be used clinically that relate to genomic perturba-
tions and disease transmission. It is hoped that nonintegrat-
ing methods of reprogramming would provide a satisfactory
safety profile, but whether this is the case after transplantation
of iPSC progeny needs to be rigorously tested. Safety concerns
regarding oncogene expression, viral immunogenicity, and ge-
netic instability of hiPSCs may be averted with further im-
provements for derivation and expansion, making this a feasible
cell source for future therapeutic purposes.327
Human PSC lines that possess characteristics that thwart
or downregulate adaptive and/or innate immune responses
may be valuable cell lines for clinical application. For example,
Rong et al302 expressedmolecules which blocked costimulatory
signals and downregulated immune responses to hESC prog-
eny. Other strategies might involve modifying HLA antigen
expression on hPSCs or expressing proteins that promote
regulatory T cells.
Direct reprogramming usually involves adding pancreatic
transcription factor genes analogous to the addition of pluri-
potency genes for stem cell reprogramming. However, the
process of reprogramming with integrating lentiviral vectors
can alter the genome leading to malignant transformation or
reduced differentiation. Although nonintegrating vectors ex-
ist, those containing pancreatic transcription factors are not
widely available for use.
There is a need for better cell delivery devices taking ad-
vantage of material science, 3-dimensional culture, nanotech-
nology, matrix biology, improved oxygen delivery platforms,
and better encapsulation technology. Many encapsulation
methods currently induce fibrosis after implantation in large
animals despite promising results in rodents. Materials and
devices that reduce the fibrogenic foreign body host response
while still allowing macromolecular nutrients to bathe cells
and excluding immune cells, antibodies and ideally cytokines
would be a valuable transplant vehicle. Combining platforms
could provide a more physiological environment for growth,
differentiation, and survival of the cells long term.
Although islets can function in vivo after transplant as
long as they are well vascularized, challenges still exist with
identifying an optimal site for islets and β-cell grafts derived
from hPSCs. Ideally, one would prefer to transplant alloge-
neic islets (or human stem cell-derived endocrine cells) into
patients into a site that is safe, accessible with minimal risk,
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and optimal from the point of view of allowing adequate vol-
ume, is not highly immunogenic, is well vascularized, and is
free from instant blood-mediated inflammation. Considering
these requirements, the venous sac may prove a suitable
transplant site for allogeneic islets in human, but only preclin-
ical studies have been conducted to date.328 Lymph nodes
and the omentum have also been shown to be potential sites
for islet transplantation.329,330 Ultimately, additional bioen-
gineering approaches may be needed to incorporate scaffolds
and ECM molecules to construct well-vascularized tissue
from single cells. Several studies have made headway in mak-
ing devices or scaffolds for appropriate islet cell engraft-
ment.331-333 A clinical study is currently underway to study
whether a subcutaneously implanted, prevascularized scaffold
may be suitable for islet transplantation (http://clinicaltrials.
gov/ct2/show/NCT01652911), and this has clear relevance
for stem cell-derived cells. Further studies in this arena and ap-
provals through the FDA will undoubtedly inform future re-
lated studies with stem cell-derived β cells.
Summary and Speculation on Therapeutic Impact
Rapid progress and expansion of knowledge continues to
characterize the field of deriving β cells from stem cells which
began approximately 15 years ago, at which time the tran-
scriptional network of pancreas development and nature of
human definitive endoderm was entirely unknown. We have
come a long way since then. Yet, the majority of research re-
mains in the preclinical realm focused on optimizingmethods
for the in vitro conversion of stem cells or somatic cells to
high yield, functional cells that resemble adult human islets/
β cells. Given the complexity of the developmental processes
scientists are trying to mimic, it is not surprising that this has
proven such a difficult task. Nonetheless, real progress is oc-
curring, and there is tremendous anticipation that physiolog-
ically normal adult β-like cells will be achieved in the very
near future. Even without achieving this in vitro milestone,
companies, such as ViaCyte, Inc (http://viacyte.com), are
moving ahead with pilot clinical trials. ViaCyte, Inc has pro-
posed a phase I safety and dosage trial combining an hESC-
derived pancreatic progenitor cell product delivered in a
macroencapsulation device and transplanted into T1DM re-
cipients. How this trial and others like it unfold will signifi-
cantly affect the public's and investor's impressions of the
field's potential. The results will either embolden others to
propose additional clinical pilot trials or send the field back
to the drawing board. Still, many unanswered questions need
to be addressed and new technologies devised to support the
responsible development of the field. Given the steady prog-
ress and new innovations the field has witnessed over the last
several years, many are confident that the existing challenges
will ultimately be overcome and that an effective and safe
stem cell-based β cell replacement therapy will emerge in
the coming decade.
Summary of Research Priorities
(1) Recent reports highlight progress in achieving refined dif-
ferentiation protocols for driving human pluripotent stem
cells to β-like cells with improved physiological function
and greater capacity for more rapid correction diabetes
in mice. However, further work is needed to understand
the reason for why these cells still do not exhibit normal
stimulus-secretion coupling or dynamic insulin release in
perfusion assays.
(2) Additional studies evaluating host alloimmune and autoim-
mune responses to encapsulated and unencapsulated hu-
man pluripotent stem cell-derived β cells, in both the
syngeneic and allogeneic settings, are needed.
(3) The stem cell-derived β cell therapy field would benefit by
testing strategies incorporating new encapsulation technol-
ogies, novel cellular deliver methods and sites, and innova-
tive tissue engineering approaches.
(4) Further experimental work is needed to study the ability to
directly reprogram somatic cells into β-like cells and assess
their function in vitro and in animal models.
(5) Teratoma formation is a key safety issue with the potential
therapeutic application of human pluripotent stem cell-
derived β cells. Studies which define this risk and assays
that better predict this risk would advance the field.
b CELL REGENERATION FROM PROLIFERATION
AND NEOGENESIS
Current State of the Field
There is a great need to find sources of β cells that can be
used to replenish those that have been lost in diabetes. This
commentary focuses on the potential of the pancreas to re-
generate β cells that can reverse the diabetic state. There are
reasons to be optimistic that new β cells can be generated
by proliferation of existing β cells and by neogenesis, the pro-
duction of new islet cells from non-islet cells in the pancreas
or other organs.
The purpose of this short commentary to discuss the poten-
tial for β cell regeneration in the human pancreas that could
be exploited to replenish the β-cell deficit of people with both
T1DorT2D.Themajorquestionsbeingaddressedarewhether
β`-cell replication can be significantly enhanced and whether
there are cells in the endocrine pancreas or other organs that
can serve as precursors for the formation of newβ cells.
Is There Significant β Cell Turnover in the Adult
Human Pancreas?
Some have argued that virtually all of one's β cells develop
by the end of young adulthood and that no new β cells ap-
pear during later adult life in humans.334-336 One argument
against significant human β-cell turnover comes from nega-
tive studies using in vivo thymidine analog incorporation
and radiocarbon dating.334 Despite these conclusions, other
data support the presence of some level of β-cell turnover.
For example, we know there is a constant loss of β cells as ev-
idenced by staining for terminal deoxynucleotidyl transferase
dUTP nick end labeling337 and other makers of death, yet β
cell mass is well maintained for decades.338,339 For this rea-
son, there must be some generation of new β cells to keep
up with cell loss. Moreover, evidence suggests some expan-
sion of β-cell mass in obesity and pregnancy.337,340 The as-
sumption that the process is slow is supported by studies
quantifying the accumulation of lipofucsin, a marker of ag-
ing, in a very high percentage of β cells.341
Evidence forβCell Replication in Adult Human Pancreas
Much of the evidence that β cells do not replicate comes
from studies done on pancreases obtained at autopsy or from
cadaver donors.335,342 The most commonly used tool for
assessing β-cell replication is Ki67, but it is well known in
studies of cancer pathology that the numbers of mitotic
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figures and Ki67 positivity fall with warm and cold ische-
mia.343,344 This has also been recently demonstrated with
mouse and pig pancreases subjected to autopsy conditions
and evaluated with Ki67.345 These findings support the like-
lihood that the negligible replication rates found with Ki67
have led to erroneous conclusions. They also fit with the find-
ing that Ki67 positivity in β cells can be found in fresh surgi-
cal specimens of pancreas and in human islets transplanted
under the kidney capsule of immunodeficient mice.346
The actual rate of β-cell birth from replication is very diffi-
cult to estimate because Ki67 positivity is not necessarily
equated with the generation of new cells. However, if β
cells in adult humans have 0.4% Ki67 positivity, and
Ki67 positivity lasts 12 hours, and if there were no neo-
genesis or apoptosis, β-cell mass could more than double
in less than a year. However, Ki67 positivity can be found
in cells that do not divide but are arrested in cycle. It can
also be associated with DNA damage and apoptosis.347 Al-
though many unknowns remain, there is now good evi-
dence that there is some capacity for regeneration of β
cells from replication in adult human pancreases.
Evidence forβCell Neogenesis in Adult Human Pancreas
Islet neogenesis in rodents and humans remains a contro-
versial topic.348,349 Lineage tracing experiments in mice have
provided mixed results, and it is unlikely that similar studies
can be done with human tissue. The evidence in support of
neogenesis remains circumstantial, some of it stronger than
others. For example, the presence of insulin-stained cells in
the duct epithelium and the finding of increased numbers of
single and small clumps of β cells in human pregnancy and
in other situations may be suggestive but are hardly defini-
tive.340,350,351 One cannot be certain that these small clumps
of β cells did not arise from replication of a few existing cells.
However, finding cells in the duct epithelium that costain
for insulin and cytokeratin 19 carry more weight350 be-
cause they suggest a dynamic process. In addition, pancre-
atic intraductal neoplasms are rarely seen before age
35 years, but are found in 60% of non-neoplastic pancreases
by age 45 years and in 75%by age 55 years.352 Pancreatic intra-
ductal neoplasms can frequently contain significant numbers
of islet hormone-positive cells.
Is There Evidence That β Cell Growth can be Stimulated
in the Adult Pancreas?
The β cell mass is modestly increased by 30% to 50% in
insulin-resistant obese human subjects.337,339 Another exam-
ple of increased β-cell mass is the normal human preg-
nancy.340 Increased β-cell mass and high circulating GLP-1
levels have been seen in some subjects after bariatric sur-
gery353; however, the cause-and-effect relationship between
the two has not been established. On the negative side, sub-
jects with T2D have been treated for years with GLP-1 ago-
nists and dipeptidyl peptidase-4 inhibitors, yet no evidence
for increased β cell functional mass has emerged after drug
treatment was stopped.354
Patients with longstanding (over 50 years) T1D can rou-
tinely be found to have some β cells in their autopsied
pancreases.355 The question of whether these cells are resistant
to immune killing has not been answered. These could be a
subset of uniquely strongβ cells that survived from childhood,
but a more attractive hypothesis is that new β cells are gener-
ated continuously from neogenesis and then killed by autoim-
munity. This possibility is supported by the presence of islet
cell antibodies in these subjects, by the finding of many single
and small clusters of β cells in the pancreases, which suggest
neogenesis, and by the observation of some lymphocytes in
the few remaining islets of these pancreases.
What Causes β Cell Death?
At least some β cells have a limited life span with an apo-
ptotic death. Perhaps some cells live for decades, although
other die early for unknown reasons. One possibility is that
islets and most other organs have a natural remodeling pro-
cess, such that cell birth and apoptosis serve as mechanisms
to facilitate structural change.
In the development of both T1D and T2D, there has been
much speculation about what might cause an increased rate
of cell death other than immune destruction.356 Although
usually discussed as being important for T2D, the same prob-
lems must be faced by the residual β cells of T1D. The reality
is that we have little idea about which processes are the most
important pathways to death, but attention has focused on
the following candidates:
(a) Glucose toxicity (glucotoxicity): Clearly, hyperglycemia,
even in the range of just impaired glucose tolerance, has
a deleterious influence upon β cell function, most notably
acute GSIS. There is currently considerable interest in the
dedifferentiation of β cells that occurs in a hyperglycemic
environment.356,357 Some of these phenotypic changes
are presumably responsible for dysfunctional insulin se-
cretion. Importantly, insulin secretion rapidly returns to
normal in T2D shortly after normoglycemia is restored
by bariatric surgery.358 Little is known about the molec-
ular mechanisms through which glucotoxicity might
cause β cell death. The descriptive term “overwork” is
often used and it would be helpful to have this concept
better defined.
(b) Lipotoxicity and glucolipotoxicity: Almost all of the evi-
dence supporting the presence of lipotoxicity or glucolipo-
toxicity comes from in vitro experiments in which free
fatty acid such as palmitate are added to isolated islets or
β cell lines. Palmitate and other free fatty acids certainly
have toxic effects, and as such can be useful to examine
stress and death pathways. However, do FFAs exert ad-
verse effects on β cells in real life? As of yet, the evidence
that this occurs in vivo in human or animal diabetes is
sparse and unconvincing.359,360 Moreover, it is difficult
to find correlations between β cell dysfunction and FFA
levels as subjects develop diabetes, whereas the correlation
between rising glucose levels is very strong.361
(c) ER stress: There are good reasons to think that ER stress
from the secretory demands of insulin resistance and hy-
perglycemia leads to the demise of some β cells362 but we
do not have good markers that can follow the process.
(d) Oxidative stress (ROS): Again, there are many reasons to
think that oxygen radicals could cause cell death resulting
from β cell “overwork” or the challenges of the diabetic
environment,363 but this process also lacks markers.
(e) Amyloid: Amyloid deposits are found in many of the islets
of people with T2D but there are also few in normoglycemic
obese subjects with insulin resistance. The amyloid deposits
are formed by fibrils of IAPP and a strong case has been
made the initially formed IAPP oligomers can damagemem-
branes and cause cell death.364,365
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The Research Agenda
CanWe Significantly Increaseβ-CellMass by Stimulating
β-Cell Replication Either In Vivo or In Vitro?
Much has been learned about the cell cycle mechanisms in
murine and human β cells.366-368 In addition, various com-
pounds that can stimulate β-cell replication have been identi-
fied by high-throughput screening.369,370 There has been a
recent identification of betatrophin, which is thought to be
a factor secreted by insulin-resistant livers that can stimulate
β cell replication.371 Its mechanism of action has not yet been
defined.With all of these works, the differences betweenmice
and humans must be carefully defined because β-cell turn-
over in mice is far higher than that in humans. Research on
this topic remains active and promising.
It would be ideal if an intervention could be identified that
could stimulate β-cell replication with no side effects just
enough to restore that β-cell mass to normal. However, it is
hard to imagine that such a safe-specific drug with definable
activity will be developed in the near future. It should be
more feasible to find a way to enhance replication of β cells
from isolated islets in vitro, whereupon the cell product could
be carefully characterized and then could be transplanted.
What Are The prospects for Significantly Increasing
β Cell Mass by Stimulating Neogenesis
Either In Vivo or In Vitro?
In Vivo Possibilities
Similar to the situationwith replication, an effective in vivo
treatment to effectively induce neogenesis will probably be
very difficult to develop. However, a striking recent result
found that in alloxan diabetic mice significant recovery of
functional β-cell mass from terminally differentiated acinar
cells could be induced by short-term growth factor therapy
(epidermal growth factor and ciliary neurotrophic factor),
thus providing potential avenues for drug development.372
Another notable finding is that pancreatic exocrine cells can
be reprogrammed to become β-like cells by injections into
mouse pancreas of adenoviruses carrying 3 transcription fac-
tors, Ngn-3, Pdx-1, and MafA, which are important for β
cell development and maintenance.373
In Vitro Possibilities
An increasing number of investigators are focusing on
ways to generate β cells from exocrine cells in vitro. The first
encouraging result was a demonstration in 2000 that cul-
tured human duct cells covered withMatrigel could produce
new islet cells,374 a result that was confirmed shortly thereaf-
ter.375 There continues to be a lot of work exploring the po-
tential of converting pancreatic duct cells,374,376 centroacinar
cells,377 or acinar cells372 to new islet cells and even fully
formed islets.
To obtain sufficient numbers of islet cells from exocrine
cells, it will be necessary to expand the exocrine cells in vitro.
One approach is to exploit natural branching morphogenesis
to create organoids in tissue culture (481). Another is to ex-
pand exocrine or even islet cells in tissue culture through
the process of epithelial-mesenchymal transition and then
use various differentiation factors to produce islet cells that
might be used for transplantation.379
Among recent examples of progress, the Clevers group
found a way to activate duct cells to express Lgr5, a marker
for adult stem cells.380 These have a propensity to develop
into organoids, which allows expansion, and then when
transplanted with fetal pancreas into recipient mouse kidneys
can form islet cells. The group of Kim381 was able to expand
purified CD133+ human duct cells into epithelial spheres and
then reprogram them with adenoviruses carrying Ngn-3,
Pdx-1, MafA, and Pax6 into human IPCs. A similar approach
has been used by the group of Docherty.376
Islet Cell Plasticity
There has been considerable interest in the possibility that
1 type of islet cell can be converted to another. Leading the
way, the Herrera group used lineage tracing to show that af-
ter severe β-cell ablation with diphtheria toxin, some of the
residual α cells could assume a β-cell phenotype.382 With ge-
netic engineering, the group of Collombat showed that ex-
pression of Pax4 in α cells led to the conversion of these
cells to β cells.383 Another example comes from lineage trac-
ing studies with diabetic Foxo1 knockoutmice, inwhich con-
version for α cells to β cells was demonstrated.357 A major
question is whether such conversion happens naturally to
any meaningful extent. A study using extreme ablation with
streptozotocin found no evidence for such regeneration.384
The more important question is whether this is a pathway
that can be exploited for therapeutic purposes. Although
challenging, there are enough α cells to hope that conversion
and expansion might provide enough β cells to provide ther-
apeutic benefits.
CONCLUSIONS
Much work is now being done to find a new source of
β cells that can be used to replenish the β-cell deficit of diabe-
tes. There is well-justified excitement about progress in con-
verting hESCs and hiPSCs to β cells. However, there are
also impressive advances in findingways to exploit the regen-
erative potential of cells in the adult human pancreas. It is es-
sential that these and other promising avenues be intensively
evaluated.
Summary of Research Priorities
(1) Evidence is presented that there is a slow rate ofβ cell turn-
over in the human adult pancreas, occurring from replica-
tion of existing β cells and the birth of new β cells through
neogenesis. The potential of exploiting this for clinical ap-
plication is being explored by many laboratories.
(2) There is also a slow rate of β-cell death in the adult human
pancreas occurring through the processes of apoptosis and
necrosis.
(3) There is evidence that the rate ofβ cell death is increased in
T2D, and the contributing mechanisms are thought to in-
clude endoplasmic reticulum stress, toxic amyloid oligo-
mers, oxidative injury, and the ill-defined processes of
overwork and glucose toxicity.
Report of Meeting Survey
The quest for a safe and efficacious form of β-cell replace-
ment is at a unique juncture in its history with multiple ther-
apies with either existing or potential application that will in
the coming years compete for a place in the care of patients
with T1D and potentially T2D. To gain a sense from the ex-
pert group, we assembled in Oxford as to their opinion of
what the field of β-cell replacement would look like in the
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future, we conducted a survey on the final day of themeeting.
The survey asked each participant to assign their predicted
market share at 5, 10, and 20 years in the future of clinical
β cell replacement activities to each of the therapies we
discussed: allogeneic islets, xenogeneic islets (encapsulated
or not), tolerance for allogeneic islets, tolerance for xenoge-
neic islets, AP, ES-derived β cells, encapsulated ES-derived β
cells, IP-derived β cells, and β-cell regeneration from prolifer-
ation or neogenesis. For each timepoint, each survey partici-
pant assigned 100% of market share among these therapies.
The results in Figure 1 reveal that at 5 years hence, our
panel believes that the market will be dominated by isolated
allogeneic islets and the AP with anticipated minor contribu-
tions from IPs and ES-derived β cells, xeno islets, and toler-
ance. About 50% of respondents predicted no or negligible
contributions from tolerance to xeno islets, endogenous islet
regeneration/proliferation and IPs derivedβ cells. At 10 years,
the most significant increase was in the predicted role of en-
capsulated ES-derived β cells and further expansion of reli-
ance on AP. There were also minor increases in xeno islets,
tolerance to allo islets, IP-derived β cells, and continued sig-
nificant predicted activity in allo islets. By 20 years, hence,
our experts predicted market domination by IP-derived β
cells and APwith contraction of allo-islet activity andmodest
expansion of β cell proliferation/regeneration. The survey
has obvious limitations including a small sample size and
pool of respondents selected for meeting participation based
on expertise in a given areas that likely carries with it an asso-
ciated bias.
Summary
Biologic or biomechanical therapy capable of replacing
the β cell mass has the potential to positively impact the
health and well being of millions of people with insulin-
dependent diabetes. Research in this area stands at a pivotal
moment at which a number of viable strategies exist or are
under development. Broad application depends on achiev-
ing both technical and financial feasibility. The ultimate
goal of a “true cure,” in which diabetic individuals achieve
euglycemia with a single procedure associated with minimal
risk, without long-term toxic drugs, and unfettered by external
devices and/or frequent monitoring, appears to still be some
years away. However, dramatic progress has been achieved to-
ward themore proximate objectives of improved glycemic con-
trol and elimination of hypoglycemia and long-term vascular
complications.
Long-term whole organ pancreas and isolated islet results
have improved significantly over the last decade, with the latter
now approaching the success of the former in insulin indepen-
dence rates at the 5-year mark. It seems likely that allogeneic
pancreas and islet transplantation will remain a treatment of
choice for the foreseeable future in kidney recipients already
obligated to lifelong immunosuppression until a more com-
plete and permanent restoration of euglycemia is available.
Nascent tolerance promoting protocols could aid in improving
the risk-to-benefit balance for both islets andwhole organ pan-
creas. With the present supply of transplantable pancreases
used optimally, nomore than 13%of the annual incident cases
of T1D can be cured. In practical terms though, today, fewer
than 5% of the annual incident cases are transplanted. The re-
ality of the limited supply of deceased donor organs ultimately
constrains the impact of islet and pancreas transplantation and
compels researchers to press forward to develop broader strat-
egies such as the AP, xenogeneic islets, and stem cell-derived β
cells for which the supply will be limitless; in these areas, recent
progress has been most impressive.
The AP continues to be refined withmore sophisticated de-
livery algorithms, improved sensors and exploration of mo-
bile device control. For xenogeneic islets, dramatic progress
is evident in the long-term survival of porcine islets in primates
using genetically modified donors and/or improved biologic
immunosuppressants. Microencapsulation and macroencap-
sulation devices that exclude direct immunity by physical
means may further aid in fostering xenogeneic islet graft sur-
vival but will likely find their primary place in the contain-
ment and protection of early versions of stem cell–derived
allogeneic β cells. Deriving functional β cells from stem cells
has experienced the most celebrated recent advances. Im-
proved differentiation protocols that permit large scale/
unlimited production of IPCs are now available, and although
“normal” β-cell function has not yet been achieved, the ever
quickening pace of progress suggests they are not far off. Im-
portantly, this therapeutic modality will ultimately need to
confront the likely requirement for a containment device
FIGURE 1. Expected changes in β cell replacement over time. before the conclusion of the conference, a web based survey was completed by
the participants seeking their individual opinion as to what portion of the β-cell replacement market would be captured by the existing and po-
tential therapies discussed at the meeting. For each of the time horizons of 5, 10, and 20 years, respondents allocated predicted market share
between 9 potential therapeutic options. The graph shows the average market share awarded to specific therapies at 5, 10, and 20 years.
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and the need to be retransplanted periodically. These blem-
ishes notwithstanding, the tremendous perceived potential of
the approach for clinical application is evident in the huge
venture capital investment that was rapidly garnered after
the report of the most recent advance in embryonic stem cell
differentiation into proper β cells. Consistent with the infor-
mal survey we conducted, iPS-derived β cells, which currently
suffer from regulatory hurdles and the lack of a viable busi-
ness model, and the seemingly more remote regeneration of
nativeβ cells, may offer the ultimate chance for a personalized
true cure of insulin-dependent diabetes by avoidance of bar-
rier devices and toxic immunosuppressive drugs.
The research agenda we have detailed is designed to facil-
itate full exploration of the potential of each proposed β-cell
replacement solution so the optimal therapy is advanced as
quickly as possible. Success in this endeavor will require
broad and deep financial support from philanthropic (JDRF,
Diabetes Research and Wellness Foundation, ADA, and so
on) and public funding agencies worldwide; the investment
needed is large but the potential reward will be profound.
It is imperative that high impact, scientifically sound ap-
proaches are not overwhelmed by industry, private, or ven-
ture capital-supported priorities just because they hold a
more lucrative near-term business model; scientific merit
should dictate the course. The adherence of the historical
funding agencies to traditional peer-reviewed methodology
will be the incubator of novel approaches. This is a rapidly
evolving landscape, and new data and novel ideas may radi-
cally divert the path forward. However, the diverse recent
progress is tangible and undeniable, and the next decade is
bound to witness a fascinating unfolding of competing solu-
tions to cure insulin-dependent diabetes.
Our assessment of the data presented creates the opportu-
nity for IPITA/TTS to endorse the following broad agenda
for specific support by the peer-reviewed agencies.
(1) Allogeneic islet transplantation using novel strategies to
facilitate engraftment, enhance graft longevity and ulti-
mately gain immunosuppression-free survival in adult and
pediatric patients.
(2) Xenogeneic islet-based approaches with and without
encapsulation.
(3) Stem cell–based therapy of diabetes.
(4) Regeneration based therapy.
(5)Mobile device–based control of glucose sensing-insulin de-
livery: AP.
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